|
G |
Fabp1 |
fatty acid binding protein 1 |
multiple interactions |
ISO EXP |
[FABP1 protein affects the transport of Dronabinol] which affects the abundance of 11-hydroxy-delta(9)-tetrahydrocannabinol 11-hydroxy-delta(9)-tetrahydrocannabinol affects the folding of and results in increased stability of FABP1 protein; 11-hydroxy-delta(9)-tetrahydrocannabinol inhibits the reaction [anandamide analog binds to FABP1 protein] 11-hydroxy-delta(9)-tetrahydrocannabinol inhibits the reaction [11-(dansylamino)undecanoic acid binds to FABP1 protein] |
CTD |
PMID:30232874 PMID:31110286 |
|
NCBI chr 4:99,063,181...99,066,957
Ensembl chr 4:99,063,181...99,066,954
|
|
G |
Trpv2 |
transient receptor potential cation channel, subfamily V, member 2 |
multiple interactions |
EXP |
11-hydroxy-delta(9)-tetrahydrocannabinol binds to and results in increased activity of TRPV2 protein |
CTD |
PMID:18550765 |
|
NCBI chr10:48,903,540...48,925,036
Ensembl chr10:48,903,540...48,925,030
|
|
|
G |
Abhd12 |
abhydrolase domain containing 12, lysophospholipase |
increases hydrolysis |
ISO |
ABHD12 protein results in increased hydrolysis of glyceryl 2-arachidonate |
CTD |
PMID:18096503 |
|
NCBI chr 3:146,630,298...146,690,375
Ensembl chr 3:146,630,299...146,690,375
|
|
G |
Abhd6 |
abhydrolase domain containing 6, acylglycerol lipase |
increases hydrolysis |
ISO |
ABHD6 protein results in increased hydrolysis of glyceryl 2-arachidonate |
CTD |
PMID:18096503 |
|
NCBI chr15:18,647,903...18,695,133
Ensembl chr15:18,647,844...18,695,133
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
increases expression multiple interactions |
EXP |
glyceryl 2-arachidonate results in increased expression of ACTA2 mRNA Acetaldehyde promotes the reaction [glyceryl 2-arachidonate results in increased expression of ACTA2 mRNA] |
CTD |
PMID:21863215 |
|
NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
|
|
G |
Arrb1 |
arrestin, beta 1 |
multiple interactions |
ISO |
glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]] |
CTD |
PMID:31024316 |
|
NCBI chr 1:164,502,099...164,573,947
Ensembl chr 1:164,502,389...164,593,139
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
ISO |
[GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; [GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; glyceryl 2-arachidonate promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB2 protein] |
CTD |
PMID:31024316 |
|
NCBI chr10:57,040,252...57,048,045
Ensembl chr10:57,040,267...57,048,134
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in increased expression of ATF4 mRNA iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of ATF4 mRNA] |
CTD |
PMID:32357311 |
|
NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of BTG2 mRNA |
CTD |
PMID:28095641 |
|
NCBI chr13:50,913,185...50,916,944
Ensembl chr13:50,913,180...50,916,982
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of CCL2 protein |
CTD |
PMID:15115777 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ces1d |
carboxylesterase 1D |
increases hydrolysis multiple interactions |
ISO |
CES1 protein results in increased hydrolysis of glyceryl 2-arachidonate [CES1 protein results in increased hydrolysis of glyceryl 2-arachidonate] which results in increased chemical synthesis of Arachidonic Acid |
CTD |
PMID:21049984 |
|
NCBI chr19:15,195,514...15,239,827
Ensembl chr19:15,033,108...15,239,821
|
|
G |
Ces2h |
carboxylesterase 2H |
increases hydrolysis multiple interactions |
ISO |
CES2 protein results in increased hydrolysis of glyceryl 2-arachidonate [CES2 protein results in increased hydrolysis of glyceryl 2-arachidonate] which results in increased chemical synthesis of Arachidonic Acid |
CTD |
PMID:21049984 |
|
NCBI chr19:37,052,555...37,067,176
Ensembl chr19:37,052,556...37,067,156
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions increases expression |
ISO EXP |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; CNR1 protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]] glyceryl 2-arachidonate results in increased expression of CNR1 mRNA [GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA]; glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]] Acetaldehyde promotes the reaction [glyceryl 2-arachidonate results in increased expression of CNR1 mRNA]; Nitroglycerin affects the reaction [glyceryl 2-arachidonate affects the activity of CNR1 protein] |
CTD |
PMID:12657697 PMID:15899896 PMID:16775503 PMID:21863215 PMID:23894352 PMID:26209559 PMID:28095641 PMID:31024316 |
|
NCBI chr 5:49,307,584...49,333,064
Ensembl chr 5:49,311,030...49,333,056
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
multiple interactions affects response to substance |
ISO |
[GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; [SR 144528 binds to and results in increased activity of CNR2 protein] inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CXCL8 protein]; CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased expression of CXCL8 protein]; CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; Pertussis Toxin inhibits the reaction [CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]]; SR 144528 inhibits the reaction [CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]] CNR2 gene SNP affects the susceptibility to glyceryl 2-arachidonate |
CTD |
PMID:10617657 PMID:15115777 PMID:20124950 PMID:31024316 |
|
NCBI chr 5:154,242,010...154,268,126
Ensembl chr 5:154,260,062...154,268,126
|
|
G |
Creb3l3 |
cAMP responsive element binding protein 3-like 3 |
multiple interactions increases expression |
ISO |
glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CREB3L3 mRNA] |
CTD |
PMID:23894352 |
|
NCBI chr 7:11,490,852...11,499,287
Ensembl chr 7:11,490,852...11,499,282
|
|
G |
Crh |
corticotropin releasing hormone |
increases abundance |
ISO |
CRH protein results in increased abundance of glyceryl 2-arachidonate |
CTD |
PMID:26821211 |
|
NCBI chr 2:104,459,999...104,461,863
Ensembl chr 2:104,459,999...104,461,863
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA] |
CTD |
PMID:23894352 PMID:28095641 |
|
NCBI chr 9:81,968,285...81,998,213
Ensembl chr 9:81,968,332...81,998,169
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions increases expression |
ISO |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA] |
CTD |
PMID:23894352 PMID:28095641 |
|
NCBI chr 5:19,358,734...19,368,431
Ensembl chr 5:19,358,734...19,368,431
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
increases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA] |
CTD |
PMID:23894352 |
|
NCBI chr 2:102,701,903...102,871,257
Ensembl chr 2:102,701,903...102,871,257
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
increases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA] |
CTD |
PMID:23894352 PMID:28095641 |
|
NCBI chr 8:130,548,418...130,550,388
Ensembl chr 8:130,548,418...130,550,388
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in increased expression of DDIT3 mRNA; glyceryl 2-arachidonate results in increased expression of DDIT3 protein iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of DDIT3 mRNA]; iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of DDIT3 protein] |
CTD |
PMID:32357311 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
multiple interactions increases phosphorylation |
ISO |
GSK2656157 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of EIF2S1 protein]; iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:32357311 |
|
NCBI chr 6:102,048,372...102,073,041
Ensembl chr 6:102,048,372...102,073,041
|
|
G |
Esrrg |
estrogen-related receptor gamma |
increases abundance |
ISO |
ESRRG protein results in increased abundance of glyceryl 2-arachidonate |
CTD |
PMID:31912162 |
|
NCBI chr13:106,063,799...106,683,353
Ensembl chr13:106,463,368...106,683,436
|
|
G |
Fmr1 |
FMRP translational regulator 1 |
multiple interactions |
ISO |
[FMR1 gene mutant form results in increased activity of MGLL] which results in increased degradation of glyceryl 2-arachidonate |
CTD |
PMID:20393458 |
|
NCBI chr X:154,684,924...154,722,369
Ensembl chr X:154,684,935...154,722,314
|
|
G |
Fyn |
FYN proto-oncogene, Src family tyrosine kinase |
multiple interactions |
EXP |
FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:12657697 |
|
NCBI chr20:44,436,354...44,630,316
Ensembl chr20:44,436,403...44,630,317
|
|
G |
Grk2 |
G protein-coupled receptor kinase 2 |
multiple interactions |
ISO |
[GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; [GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]] |
CTD |
PMID:31024316 |
|
NCBI chr 1:219,536,220...219,544,329
Ensembl chr 1:219,536,220...219,544,328
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of HSPA5 mRNA |
CTD |
PMID:32357311 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in decreased expression of IL1B mRNA glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]] |
CTD |
PMID:16364651 PMID:30611738 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
glyceryl 2-arachidonate metabolite inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased secretion of IL2 protein]; T 0070907 inhibits the reaction [glyceryl 2-arachidonate metabolite inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased secretion of IL2 protein]] |
CTD |
PMID:21511917 |
|
NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
|
|
G |
Il6 |
interleukin 6 |
decreases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in decreased expression of IL6 mRNA glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]] |
CTD |
PMID:16364651 PMID:30611738 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CREB3L3 mRNA]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA] |
CTD |
PMID:23894352 |
|
NCBI chr 1:215,856,967...215,858,034
Ensembl chr 1:215,856,971...215,858,034
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein; U 0126 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein] |
CTD |
PMID:12657697 |
|
NCBI chr 8:69,134,218...69,722,573
Ensembl chr 8:69,134,223...69,164,758
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein; U 0126 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein] |
CTD |
PMID:12657697 |
|
NCBI chr 7:11,458,971...11,478,520
Ensembl chr 7:11,458,967...11,478,489
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions decreases phosphorylation |
ISO EXP |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein glyceryl 2-arachidonate results in decreased phosphorylation of MAPK1 protein 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in decreased phosphorylation of MAPK1 protein]; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:12657697 PMID:31917333 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases phosphorylation |
ISO EXP |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein glyceryl 2-arachidonate results in decreased phosphorylation of MAPK3 protein 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in decreased phosphorylation of MAPK3 protein]; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:12657697 PMID:31917333 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mgll |
monoglyceride lipase |
multiple interactions affects abundance increases degradation increases abundance increases hydrolysis |
EXP ISO |
[Chlorpyrifos results in decreased activity of MGLL protein] which results in increased abundance of glyceryl 2-arachidonate; JZL 184 inhibits the reaction [MGLL protein results in increased hydrolysis of glyceryl 2-arachidonate] MGLL protein affects the abundance of glyceryl 2-arachidonate MGLL protein results in increased degradation of glyceryl 2-arachidonate [FMR1 gene mutant form results in increased activity of MGLL] which results in increased degradation of glyceryl 2-arachidonate; [JZL 184 results in decreased activity of MGLL protein] which results in increased abundance of glyceryl 2-arachidonate MGLL gene mutant form results in increased abundance of glyceryl 2-arachidonate |
CTD |
PMID:18096503 PMID:20393458 PMID:21507991 PMID:23761300 PMID:25030704 PMID:26209559 PMID:26642910 PMID:30301768 |
|
NCBI chr 4:120,671,436...120,773,458
Ensembl chr 4:120,671,489...120,771,088
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased activity of MPO protein]] |
CTD |
PMID:30611738 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
GSK2656157 inhibits the reaction [glyceryl 2-arachidonate results in increased cleavage of PARP1 protein] |
CTD |
PMID:32357311 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
affects localization multiple interactions |
EXP |
glyceryl 2-arachidonate affects the localization of PPARA protein [palmidrol co-treated with glyceryl 2-arachidonate] affects the localization of PPARA protein; [palmidrol co-treated with glyceryl 2-arachidonate] affects the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of PPARA protein]; glyceryl 2-arachidonate affects the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of PPARA protein] |
CTD |
PMID:31787870 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
affects binding multiple interactions increases expression |
ISO |
glyceryl 2-arachidonate metabolite binds to PPARG protein glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in decreased expression of PPARG protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]] T 0070907 inhibits the reaction [glyceryl 2-arachidonate metabolite results in increased expression of PPARG mRNA] |
CTD |
PMID:21511917 PMID:26209559 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions |
EXP |
[Indomethacin results in decreased expression of PTGS1] which results in increased activity of glyceryl 2-arachidonate |
CTD |
PMID:17245358 |
|
NCBI chr 3:15,560,685...15,582,339
Ensembl chr 3:15,560,712...15,582,344
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases metabolic processing multiple interactions |
ISO |
PTGS2 protein results in increased metabolism of glyceryl 2-arachidonate 2-chloro-5-nitrobenzanilide inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; CNR1 protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; rimonabant inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]] glyceryl 2-arachidonate inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased expression of PTGS2 mRNA]; Ibuprofen inhibits the reaction [PTGS2 protein results in increased metabolism of glyceryl 2-arachidonate] |
CTD |
PMID:18297109 PMID:21511917 PMID:26209559 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
2-chloro-5-nitrobenzanilide inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]]; glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]] |
CTD |
PMID:26209559 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions |
ISO EXP |
glyceryl 2-arachidonate results in decreased expression of TNF mRNA glyceryl 2-arachidonate inhibits the reaction [[Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein]; glyceryl 2-arachidonate inhibits the reaction [amyloid beta-protein (25-35) results in increased expression of TNF protein] glyceryl 2-arachidonate inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein] |
CTD |
PMID:12509806 PMID:16364651 PMID:30611738 PMID:30769029 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions affects response to substance |
EXP ISO |
glyceryl 2-arachidonate binds to and results in increased activity of TRPV1 protein TRPV1 protein affects the susceptibility to glyceryl 2-arachidonate |
CTD |
PMID:18550765 PMID:21949157 |
|
NCBI chr10:59,799,123...59,824,208
Ensembl chr10:59,799,123...59,824,679
|
|
G |
Yy1 |
YY1 transcription factor |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of YY1 mRNA |
CTD |
PMID:28095641 |
|
NCBI chr 6:132,702,443...132,726,848
Ensembl chr 6:132,702,448...132,727,046
|
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in decreased expression of ABCG2 mRNA]; anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]; Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]]; iodopravadoline inhibits the reaction [anandamide results in decreased expression of ABCG2 mRNA] anandamide results in decreased expression of ABCG2 mRNA; anandamide results in decreased expression of ABCG2 protein |
CTD |
PMID:30610963 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
G |
App |
amyloid beta precursor protein |
decreases response to substance decreases metabolic processing decreases abundance |
EXP ISO |
anandamide results in decreased susceptibility to APP protein APP protein results in decreased metabolism of anandamide APP protein results in decreased abundance of anandamide |
CTD |
PMID:22233683 PMID:26976670 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
ISO |
anandamide promotes the reaction [CNR1 protein affects the localization of ARRB2 protein] |
CTD |
PMID:31024316 |
|
NCBI chr10:57,040,252...57,048,045
Ensembl chr10:57,040,267...57,048,134
|
|
G |
Bdkrb1 |
bradykinin receptor B1 |
multiple interactions decreases activity |
ISO |
AM 251 inhibits the reaction [anandamide results in decreased activity of BDKRB1 protein] |
CTD |
PMID:19022239 |
|
NCBI chr 6:129,437,423...129,441,553
Ensembl chr 6:129,438,158...129,440,574
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions |
ISO |
anandamide results in increased cleavage of CASP3 protein 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [anandamide results in increased cleavage of CASP3 protein] |
CTD |
PMID:26513129 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Cd36 |
CD36 molecule |
increases expression |
ISO |
anandamide results in increased expression of CD36 mRNA; anandamide results in increased expression of CD36 protein |
CTD |
PMID:17360047 |
|
NCBI chr 4:14,150,309...14,191,498
Ensembl chr 4:14,001,761...14,249,749
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
decreases expression |
ISO |
anandamide results in decreased expression of CGA mRNA |
CTD |
PMID:30610963 |
|
NCBI chr 5:50,362,491...50,393,368
Ensembl chr 5:50,381,244...50,393,367
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
affects activity decreases expression affects binding increases activity multiple interactions |
ISO EXP |
anandamide affects the activity of CNR1 protein anandamide results in decreased expression of CNR1 protein anandamide binds to CNR1 protein anandamide results in increased activity of CNR1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased activity of CNR1]; anandamide promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; CNR1 affects the reaction [TRPV1 affects the susceptibility to anandamide]; Pertussis Toxin inhibits the reaction [anandamide results in increased activity of CNR1]; Rimonabant inhibits the reaction [anandamide results in increased activity of CNR1] [anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; rimonabant inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]]; SR 144528 inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]] |
CTD |
PMID:10871313 PMID:11408034 PMID:11891798 PMID:12657697 PMID:14504685 PMID:15453094 PMID:17557913 PMID:19147270 PMID:31024316 PMID:31199905 |
|
NCBI chr 5:49,307,584...49,333,064
Ensembl chr 5:49,311,030...49,333,056
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
affects activity affects binding multiple interactions |
ISO EXP |
anandamide affects the activity of CNR2 protein anandamide binds to CNR2 protein anandamide binds to and results in increased activity of CNR2 protein; CNR2 affects the reaction [TRPV1 affects the susceptibility to anandamide] |
CTD |
PMID:10617657 PMID:10688601 PMID:15453094 PMID:19147270 |
|
NCBI chr 5:154,242,010...154,268,126
Ensembl chr 5:154,260,062...154,268,126
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions decreases phosphorylation |
ISO |
anandamide inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]; Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]] anandamide results in decreased phosphorylation of CREB1 protein |
CTD |
PMID:30610963 |
|
NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO |
anandamide results in increased expression of DDIT3 mRNA; anandamide results in increased expression of DDIT3 protein 4-phenylbutyric acid inhibits the reaction [anandamide results in increased expression of DDIT3 protein]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [anandamide results in increased expression of DDIT3 protein] |
CTD |
PMID:21949157 PMID:26513129 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases phosphorylation multiple interactions |
ISO |
anandamide results in increased phosphorylation of EIF2S1 protein 4-phenylbutyric acid inhibits the reaction [anandamide results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:26513129 |
|
NCBI chr 6:102,048,372...102,073,041
Ensembl chr 6:102,048,372...102,073,041
|
|
G |
Ervfrd-1 |
endogenous retrovirus group FRD member 1, envelope |
decreases expression |
ISO |
anandamide results in decreased expression of ERVFRD-1 mRNA |
CTD |
PMID:30610963 |
|
NCBI chr12:25,161,130...25,168,182
Ensembl chr12:25,161,130...25,168,182
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions increases expression |
ISO |
anandamide promotes the reaction [IL1B protein results in increased expression of F3 protein] anandamide results in increased expression of F3 protein |
CTD |
PMID:27556861 |
|
NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
|
|
G |
Faah |
fatty acid amide hydrolase |
increases degradation multiple interactions affects expression |
ISO EXP |
FAAH results in increased degradation of anandamide FAAH protein results in increased degradation of anandamide [Chlorpyrifos results in decreased activity of FAAH protein] which results in increased abundance of anandamide; [Lipopolysaccharides results in decreased expression of FAAH protein] which results in increased abundance of anandamide; Nitroglycerin promotes the reaction [FAAH protein results in increased degradation of anandamide] anandamide affects the expression of FAAH protein [cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester results in decreased activity of FAAH protein] which results in decreased metabolism of anandamide; [nimesulide results in decreased expression of PTGS2] promotes the reaction [FAAH affects the metabolism of anandamide]; [PF 3845 results in decreased activity of FAAH protein] which results in decreased metabolism of anandamide |
CTD |
PMID:11556820 PMID:16131814 PMID:16886060 PMID:19515121 PMID:20702753 PMID:23761300 PMID:26642910 PMID:31121907 |
|
NCBI chr 5:134,852,899...134,872,095
Ensembl chr 5:134,852,875...134,871,775
|
|
G |
Faahl |
fatty-acid amide hydrolase-like |
increases degradation affects expression multiple interactions |
ISO |
FAAH results in increased degradation of anandamide anandamide affects the expression of FAAH protein [cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester results in decreased activity of FAAH protein] which results in decreased metabolism of anandamide; [nimesulide results in decreased expression of PTGS2] promotes the reaction [FAAH affects the metabolism of anandamide]; [PF 3845 results in decreased activity of FAAH protein] which results in decreased metabolism of anandamide |
CTD |
PMID:16131814 PMID:16886060 PMID:20702753 PMID:31121907 |
|
NCBI chr 5:134,330,204...134,349,400
Ensembl chr 5:134,331,929...134,348,995
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
multiple interactions affects binding |
EXP |
11-hydroxy-delta(9)-tetrahydrocannabinol inhibits the reaction [anandamide analog binds to FABP1 protein]; Dronabinol inhibits the reaction [anandamide analog binds to FABP1 protein] |
CTD |
PMID:30232874 |
|
NCBI chr 4:99,063,181...99,066,957
Ensembl chr 4:99,063,181...99,066,954
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
EXP |
anandamide inhibits the reaction [Nitroglycerin results in increased expression of FOS protein]; capsazepine inhibits the reaction [anandamide results in increased expression of FOS protein]; resiniferatoxin inhibits the reaction [anandamide results in increased expression of FOS protein] anandamide results in increased expression of FOS; anandamide results in increased expression of FOS protein |
CTD |
PMID:9748483 PMID:15601931 PMID:19515121 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
anandamide affects the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of TNF]; anandamide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of IL1B] |
CTD |
PMID:12813001 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Igf1 |
insulin-like growth factor 1 |
increases expression |
ISO |
anandamide results in increased expression of IGF1 protein |
CTD |
PMID:17307377 |
|
NCBI chr 7:28,412,123...28,491,815
Ensembl chr 7:28,412,198...28,486,609
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
[OMDM-1 cpd co-treated with anandamide] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein]; anandamide inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein] |
CTD |
PMID:15748152 |
|
NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
anandamide inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; anandamide inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]] anandamide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of IL1B]; anandamide promotes the reaction [IL1B protein results in increased expression of F3 protein] |
CTD |
PMID:12813001 PMID:15748152 PMID:27556861 PMID:30611738 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
anandamide inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]] |
CTD |
PMID:30611738 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Lep |
leptin |
decreases abundance decreases activity decreases transport |
ISO |
LEP protein results in decreased abundance of anandamide LEP protein results in decreased activity of anandamide LEP protein results in decreased transport of anandamide |
CTD |
PMID:16154199 |
|
NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein; U 0126 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein] |
CTD |
PMID:12657697 |
|
NCBI chr 8:69,134,218...69,722,573
Ensembl chr 8:69,134,223...69,164,758
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein; U 0126 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein] |
CTD |
PMID:12657697 |
|
NCBI chr 7:11,458,971...11,478,520
Ensembl chr 7:11,458,967...11,478,489
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein] anandamide results in increased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; AM 251 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; Hydrogen Peroxide promotes the reaction [anandamide results in increased phosphorylation of MAPK1 protein]; JTE 907 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Pertussis Toxin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; wortmannin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein] 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; Rimonabant inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:12657697 PMID:19477951 PMID:21179406 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO EXP |
anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] anandamide results in increased phosphorylation of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; AM 251 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; Hydrogen Peroxide promotes the reaction [anandamide results in increased phosphorylation of MAPK3 protein]; JTE 907 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Pertussis Toxin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; wortmannin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; rimonabant inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:12657697 PMID:19477951 PMID:21179406 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
increases expression |
ISO |
anandamide results in increased expression of MMP1 mRNA |
CTD |
PMID:16330497 |
|
NCBI chr 8:5,703,206...5,723,593
Ensembl chr 8:5,703,206...5,723,591
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
increases expression |
ISO |
anandamide results in increased expression of MMP3 mRNA |
CTD |
PMID:16330497 |
|
NCBI chr 8:5,676,608...5,698,579
Ensembl chr 8:5,676,665...5,698,579
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases expression |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [anandamide results in increased expression of MMP9 mRNA] |
CTD |
PMID:16330497 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
anandamide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; anandamide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:11891798 PMID:15748152 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
anandamide binds to and results in increased activity of PPARA protein |
CTD |
PMID:17906680 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression increases metabolic processing |
EXP ISO |
[nimesulide results in decreased expression of PTGS2] which results in increased activity of anandamide anandamide results in increased expression of PTGS2 mRNA; anandamide results in increased expression of PTGS2 protein PTGS2 results in increased metabolism of anandamide [nimesulide results in decreased expression of PTGS2] promotes the reaction [FAAH affects the metabolism of anandamide] |
CTD |
PMID:16330497 PMID:17245358 PMID:20702753 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression multiple interactions |
ISO |
anandamide results in increased expression of TIMP1 mRNA N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [anandamide results in increased expression of TIMP1 mRNA] |
CTD |
PMID:16330497 |
|
NCBI chr X:1,364,771...1,369,451
Ensembl chr X:1,364,786...1,369,384
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases abundance |
EXP ISO |
anandamide inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein] anandamide inhibits the reaction [[Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein] TNF protein results in increased abundance of anandamide anandamide affects the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of TNF] |
CTD |
PMID:12509806 PMID:12813001 PMID:20626112 PMID:30611738 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions increases response to substance increases activity affects response to substance affects binding |
ISO EXP |
3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [anandamide promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; anandamide binds to and results in increased activity of TRPV1 protein; capsazepine inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; CNR1 affects the reaction [TRPV1 affects the susceptibility to anandamide]; CNR2 affects the reaction [TRPV1 affects the susceptibility to anandamide]; Egtazic Acid inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; methyl arachidonylfluorophosphonate promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; N-(2-methyl-3-hydroxyphenyl)-5,8,11,14-eicosatetraenamide inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; Nitroprusside promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; Phenylmethylsulfonyl Fluoride promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; rimonabant inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein] TRPV1 protein results in increased susceptibility to anandamide anandamide results in increased activity of TRPV1 protein 3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [anandamide promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; anandamide binds to and results in increased activity of TRPV1 protein; bisindolylmaleimide inhibits the reaction [anandamide results in increased activity of TRPV1 protein]; Eicosapentaenoic Acid inhibits the reaction [anandamide results in increased activity of TRPV1 protein]; Tetradecanoylphorbol Acetate promotes the reaction [anandamide results in increased activity of TRPV1 protein] anandamide binds to TRPV1 protein |
CTD |
PMID:11140687 PMID:11278420 PMID:14504685 PMID:15453094 PMID:15601931 PMID:15615864 PMID:17038422 PMID:17913835 PMID:18550765 PMID:21949157 |
|
NCBI chr10:59,799,123...59,824,208
Ensembl chr10:59,799,123...59,824,679
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
anandamide results in decreased expression of and results in decreased secretion of VEGFA protein |
CTD |
PMID:15313899 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
|
G |
Actn1 |
actinin, alpha 1 |
affects methylation |
EXP |
Cannabidiol affects the methylation of ACTN1 gene |
CTD |
PMID:30521419 |
|
NCBI chr 6:103,376,557...103,470,497
Ensembl chr 6:103,375,799...103,470,555
|
|
G |
Agtrap |
angiotensin II receptor-associated protein |
increases expression |
ISO |
Cannabidiol results in increased expression of AGTRAP mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 5:164,888,069...164,898,387
Ensembl chr 5:164,886,813...164,898,420
|
|
G |
Aicda |
activation-induced cytidine deaminase |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of AICDA mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of AICDA mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 4:155,359,909...155,371,104
Ensembl chr 4:155,359,921...155,369,671
|
|
G |
Akr1b7 |
aldo-keto reductase family 1, member B7 |
increases expression |
ISO |
Cannabidiol results in increased expression of AKR1B7 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 4:61,850,256...61,879,733
Ensembl chr 4:61,850,348...61,862,526
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation |
ISO |
Cannabidiol results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:28392768 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Angptl6 |
angiopoietin-like 6 |
increases expression |
ISO |
Cannabidiol results in increased expression of ANGPTL6 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 8:21,895,523...21,902,002
Ensembl chr 8:21,895,524...21,901,829
|
|
G |
Apc2 |
APC regulator of WNT signaling pathway 2 |
affects methylation |
EXP |
Cannabidiol affects the methylation of APC2 gene |
CTD |
PMID:30521419 |
|
NCBI chr 7:12,258,468...12,280,459
Ensembl chr 7:12,258,468...12,275,609
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [APP alternative form results in increased expression of IL6 mRNA] |
CTD |
PMID:21350020 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
multiple interactions |
ISO |
[Cannabidiol co-treated with TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA; Cannabidiol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA] |
CTD |
PMID:31054246 |
|
NCBI chr 5:57,423,735...57,429,252
Ensembl chr 5:57,423,734...57,429,245
|
|
G |
Aqp4 |
aquaporin 4 |
affects expression |
ISO |
Cannabidiol affects the expression of AQP4 mRNA |
CTD |
PMID:31054246 |
|
NCBI chr18:6,766,009...6,782,757
Ensembl chr18:6,765,945...6,782,996
|
|
G |
Aqp9 |
aquaporin 9 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of AQP9 mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of AQP9 mRNA |
CTD |
PMID:21542829 PMID:30742662 |
|
NCBI chr 8:77,559,621...77,599,781
Ensembl chr 8:77,559,624...77,599,781
|
|
G |
Arpc1a |
actin related protein 2/3 complex, subunit 1A |
affects methylation |
EXP |
Cannabidiol affects the methylation of ARPC1A gene |
CTD |
PMID:30521419 |
|
NCBI chr12:11,272,609...11,294,084
Ensembl chr12:11,272,609...11,294,058
|
|
G |
Arrb2 |
arrestin, beta 2 |
affects methylation |
EXP |
Cannabidiol affects the methylation of ARRB2 gene |
CTD |
PMID:30521419 |
|
NCBI chr10:57,040,252...57,048,045
Ensembl chr10:57,040,267...57,048,134
|
|
G |
Asb2 |
ankyrin repeat and SOCS box-containing 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of ASB2 mRNA |
CTD |
PMID:27256343 |
|
NCBI chr 6:127,212,325...127,248,451
Ensembl chr 6:127,212,273...127,248,372
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of ATF3 mRNA Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of ATF3 mRNA] |
CTD |
PMID:21542829 PMID:27256343 |
|
NCBI chr13:109,817,892...109,849,632
Ensembl chr13:109,817,728...109,849,632
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression |
ISO |
Cannabidiol results in increased expression of ATF4 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
|
|
G |
Atf5 |
activating transcription factor 5 |
increases expression |
ISO |
Cannabidiol results in increased expression of ATF5 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:100,807,821...100,812,410
Ensembl chr 1:100,808,241...100,810,522
|
|
G |
Atp2a3 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3 |
increases expression |
ISO |
Cannabidiol results in increased expression of ATP2A3 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr10:59,528,849...59,560,440
Ensembl chr10:59,529,785...59,560,433
|
|
G |
Avil |
advillin |
increases expression |
ISO |
Cannabidiol results in increased expression of AVIL mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 7:70,292,565...70,310,588
Ensembl chr 7:70,292,565...70,310,588
|
|
G |
Axin2 |
axin 2 |
affects methylation |
EXP |
Cannabidiol affects the methylation of AXIN2 gene |
CTD |
PMID:30521419 |
|
NCBI chr10:97,212,483...97,238,824
Ensembl chr10:97,212,432...97,239,642
|
|
G |
Axl |
Axl receptor tyrosine kinase |
increases expression |
ISO |
Cannabidiol results in increased expression of AXL mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 1:82,550,892...82,580,761
Ensembl chr 1:82,549,420...82,580,761
|
|
G |
Bach1 |
BTB domain and CNC homolog 1 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of BACH1 mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of BACH1 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr11:27,364,913...27,398,713
Ensembl chr11:27,364,916...27,398,842
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
Cannabidiol inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein] |
CTD |
PMID:27430346 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
increases expression |
EXP |
Cannabidiol results in increased expression of BDNF protein |
CTD |
PMID:19939866 |
|
NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
affects methylation |
EXP |
Cannabidiol affects the methylation of BMP6 gene |
CTD |
PMID:30521419 |
|
NCBI chr17:26,955,142...27,112,820
Ensembl chr17:26,955,142...27,112,820
|
|
G |
Bmp7 |
bone morphogenetic protein 7 |
affects methylation |
EXP |
Cannabidiol affects the methylation of BMP7 gene |
CTD |
PMID:30521419 |
|
NCBI chr 3:170,879,972...170,955,820
Ensembl chr 3:170,879,973...170,955,399
|
|
G |
Btla |
B and T lymphocyte associated |
multiple interactions increases expression |
ISO |
Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of BTLA mRNA] Cannabidiol results in increased expression of BTLA mRNA |
CTD |
PMID:27256343 |
|
NCBI chr11:60,523,692...60,547,234
Ensembl chr11:60,524,917...60,547,201
|
|
G |
C1qa |
complement C1q A chain |
decreases expression |
ISO |
Cannabidiol results in decreased expression of C1QA mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 5:155,261,254...155,264,101
Ensembl chr 5:155,261,250...155,264,143
|
|
G |
Cacna1a |
calcium voltage-gated channel subunit alpha1 A |
affects methylation |
EXP |
Cannabidiol affects the methylation of CACNA1A gene |
CTD |
PMID:30521419 |
|
NCBI chr19:25,453,236...25,749,550
Ensembl chr19:25,526,751...25,749,550
|
|
G |
Cacna1g |
calcium voltage-gated channel subunit alpha1 G |
affects methylation |
EXP |
Cannabidiol affects the methylation of CACNA1G gene |
CTD |
PMID:30521419 |
|
NCBI chr10:82,129,071...82,197,828
Ensembl chr10:82,129,506...82,197,848
|
|
G |
Cacna1i |
calcium voltage-gated channel subunit alpha1 I |
affects methylation |
EXP |
Cannabidiol affects the methylation of CACNA1I gene |
CTD |
PMID:30521419 |
|
NCBI chr 7:121,521,787...121,619,300
Ensembl chr 7:121,511,097...121,619,283
|
|
G |
Cacna2d1 |
calcium voltage-gated channel auxiliary subunit alpha2delta 1 |
affects methylation |
EXP |
Cannabidiol affects the methylation of CACNA2D1 gene |
CTD |
PMID:30521419 |
|
NCBI chr 4:15,706,974...16,130,848
Ensembl chr 4:15,710,417...16,130,848
|
|
G |
Cacna2d2 |
calcium voltage-gated channel auxiliary subunit alpha2delta 2 |
affects methylation |
EXP |
Cannabidiol affects the methylation of CACNA2D2 gene |
CTD |
PMID:30521419 |
|
NCBI chr 8:116,154,661...116,285,643
Ensembl chr 8:116,154,736...116,284,985
|
|
G |
Cars |
cysteinyl-tRNA synthetase |
increases expression |
ISO |
Cannabidiol results in increased expression of CARS mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:216,759,367...216,801,652
Ensembl chr 1:216,759,366...216,801,656
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage |
ISO EXP |
[bafilomycin A1 co-treated with Cannabidiol] results in increased cleavage of CASP3 protein; [Cannabidiol co-treated with bafilomycin A1] results in increased cleavage of CASP3 protein; Acetylcysteine inhibits the reaction [Cannabidiol results in increased cleavage of CASP3 protein]; tin protoporphyrin IX inhibits the reaction [[bafilomycin A1 co-treated with Cannabidiol] results in increased cleavage of CASP3 protein]; tin protoporphyrin IX inhibits the reaction [Cannabidiol results in increased cleavage of CASP3 protein] Cannabidiol inhibits the reaction [Hydrogen Peroxide results in increased expression of CASP3 mRNA] |
CTD |
PMID:27430346 PMID:32708634 PMID:32733202 PMID:33076330 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp4 |
caspase 4 |
increases expression |
ISO |
Cannabidiol results in increased expression of CASP4 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 8:2,616,391...2,651,682
Ensembl chr 8:2,635,851...2,651,652
|
|
G |
Cat |
catalase |
decreases activity |
ISO |
Cannabidiol results in decreased activity of CAT protein |
CTD |
PMID:32752303 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression multiple interactions |
ISO |
Cannabidiol results in decreased expression of CCL2 mRNA Cannabidiol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CCL2 mRNA] |
CTD |
PMID:19910459 PMID:21542829 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl22 |
C-C motif chemokine ligand 22 |
multiple interactions |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of CCL22 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr19:10,674,189...10,681,145
Ensembl chr19:10,674,189...10,681,145
|
|
G |
Ccl6 |
C-C motif chemokine ligand 6 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CCL6 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr10:70,798,118...70,802,750
Ensembl chr10:70,797,124...70,802,782
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CCL7 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr10:69,423,083...69,424,933
Ensembl chr10:69,423,086...69,424,979
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression multiple interactions |
ISO |
Cannabidiol results in decreased expression of CCND1 mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of CCND1 mRNA |
CTD |
PMID:21542829 PMID:30742662 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CCNE1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980
|
|
G |
Ccne2 |
cyclin E2 |
decreases expression multiple interactions |
ISO |
Cannabidiol results in decreased expression of CCNE2 mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of CCNE2 mRNA |
CTD |
PMID:21542829 PMID:30742662 |
|
NCBI chr 5:24,434,077...24,446,406
Ensembl chr 5:24,434,872...24,446,406
|
|
G |
Cd274 |
CD274 molecule |
increases expression |
ISO |
Cannabidiol results in increased expression of CD274 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:247,519,890...247,539,659
Ensembl chr 1:247,519,939...247,537,943
|
|
G |
Cd69 |
Cd69 molecule |
multiple interactions |
ISO |
Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of CD69 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 4:163,041,147...163,049,065
Ensembl chr 4:163,041,141...163,049,084
|
|
G |
Cdc25a |
cell division cycle 25A |
decreases expression multiple interactions |
ISO |
Cannabidiol results in decreased expression of CDC25A mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of CDC25A mRNA |
CTD |
PMID:21542829 PMID:30742662 |
|
NCBI chr 8:117,953,223...117,971,552
Ensembl chr 8:117,953,444...117,971,519
|
|
G |
Cdc6 |
cell division cycle 6 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CDC6 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr10:86,819,477...86,833,301
Ensembl chr10:86,819,472...86,833,402
|
|
G |
Cdh2 |
cadherin 2 |
multiple interactions |
ISO |
[Dronabinol co-treated with Cannabidiol] inhibits the reaction [TGFB1 protein results in increased expression of CDH2 mRNA]; Cannabidiol inhibits the reaction [TGFB1 protein results in increased expression of CDH2 mRNA] |
CTD |
PMID:32049991 |
|
NCBI chr18:8,146,971...8,366,037
Ensembl chr18:8,146,971...8,360,684
|
|
G |
Cdk5r1 |
cyclin-dependent kinase 5 regulatory subunit 1 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of CDK5R1 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr10:67,862,054...67,863,255
Ensembl chr10:67,862,054...67,863,255
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of CDKN1A mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of CDKN1A mRNA |
CTD |
PMID:21542829 PMID:30742662 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
increases expression decreases expression |
ISO EXP |
Cannabidiol results in increased expression of CDKN2A mRNA Cannabidiol results in decreased expression of CDKN2A mRNA |
CTD |
PMID:21542829 PMID:32553926 |
|
NCBI chr 5:107,823,323...107,832,405
Ensembl chr 5:107,823,330...107,841,175
|
|
G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B |
increases expression |
ISO |
Cannabidiol results in increased expression of CDKN2B mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 5:107,834,353...107,857,428
Ensembl chr 5:107,845,951...107,858,104
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
multiple interactions increases expression |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of CEBPB mRNA Cannabidiol results in increased expression of CEBPB mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 3:164,424,502...164,425,933
Ensembl chr 3:164,424,515...164,425,910
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
increases expression |
ISO |
Cannabidiol results in increased expression of CFLAR mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
|
|
G |
Chac1 |
ChaC glutathione-specific gamma-glutamylcyclotransferase 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of CHAC1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 3:111,160,205...111,163,425
Ensembl chr 3:111,160,205...111,163,425
|
|
G |
Chd2 |
chromodomain helicase DNA binding protein 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of CHD2 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:134,757,934...134,873,053
Ensembl chr 1:134,757,934...134,871,167
|
|
G |
Chrna2 |
cholinergic receptor nicotinic alpha 2 subunit |
decreases expression multiple interactions |
ISO |
Cannabidiol results in decreased expression of CHRNA2 mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of CHRNA2 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr15:42,808,897...42,825,179
Ensembl chr15:42,808,897...42,825,179
|
|
G |
Chst10 |
carbohydrate sulfotransferase 10 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CHST10 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 9:45,528,928...45,559,365
Ensembl chr 9:45,528,928...45,559,140
|
|
G |
Cish |
cytokine inducible SH2-containing protein |
increases expression |
ISO |
Cannabidiol results in increased expression of CISH mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 8:116,054,547...116,059,494
Ensembl chr 8:116,054,465...116,060,723
|
|
G |
Clec4e |
C-type lectin domain family 4, member E |
increases expression |
ISO |
Cannabidiol results in increased expression of CLEC4E mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 4:156,271,087...156,276,243
Ensembl chr 4:156,270,920...156,276,304
|
|
G |
Cmpk2 |
cytidine/uridine monophosphate kinase 2 |
multiple interactions |
ISO |
Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of CMPK2 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 6:45,683,242...45,694,824
Ensembl chr 6:45,683,234...45,694,822
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions affects response to substance |
ISO EXP |
CNR1 polymorphism affects the susceptibility to [Dronabinol co-treated with Cannabidiol]; CNR1 protein promotes the reaction [Cannabidiol results in decreased secretion of SERPINE1 protein] Cannabidiol inhibits the reaction [Poly I-C inhibits the reaction [Rimonabant binds to CNR1 protein]] [1,3-dimethoxy-5-methyl-2-(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)benzene co-treated with CNR1 protein] affects the susceptibility to Cannabidiol CNR1 protein affects the susceptibility to Cannabidiol |
CTD |
PMID:20668920 PMID:30550613 PMID:31013550 PMID:31202911 |
|
NCBI chr 5:49,307,584...49,333,064
Ensembl chr 5:49,311,030...49,333,056
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
multiple interactions affects expression |
ISO |
CNR2 protein promotes the reaction [Cannabidiol results in decreased secretion of SERPINE1 protein] Cannabidiol affects the expression of CNR2 mRNA |
CTD |
PMID:20668920 PMID:32733202 |
|
NCBI chr 5:154,242,010...154,268,126
Ensembl chr 5:154,260,062...154,268,126
|
|
G |
Col4a1 |
collagen type IV alpha 1 chain |
increases expression |
ISO |
Cannabidiol results in increased expression of COL4A1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr16:83,522,162...83,632,153
Ensembl chr16:83,522,162...83,632,153
|
|
G |
Cox6a2 |
cytochrome c oxidase subunit 6A2 |
increases expression |
ISO |
Cannabidiol results in increased expression of COX6A2 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:199,624,037...199,626,255
Ensembl chr 1:199,624,037...199,624,783
|
|
G |
Cpd |
carboxypeptidase D |
multiple interactions |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of CPD mRNA |
CTD |
PMID:30742662 |
|
NCBI chr10:63,325,764...63,389,811
Ensembl chr10:63,325,199...63,389,817
|
|
G |
Cpeb1 |
cytoplasmic polyadenylation element binding protein 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of CPEB1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:143,171,457...143,278,485
Ensembl chr 1:143,171,264...143,278,485
|
|
G |
Crb1 |
crumbs cell polarity complex component 1 |
affects methylation |
EXP |
Cannabidiol affects the methylation of CRB1 gene |
CTD |
PMID:30521419 |
|
NCBI chr13:56,270,519...56,462,893
Ensembl chr13:56,270,781...56,462,834
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
increases phosphorylation multiple interactions |
ISO |
Cannabidiol results in increased phosphorylation of CREB1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cannabidiol results in increased phosphorylation of CREB1 protein]; SB 203580 inhibits the reaction [Cannabidiol results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:28601556 |
|
NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
|
|
G |
Crem |
cAMP responsive element modulator |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of CREM mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr17:57,021,704...57,090,888
Ensembl chr17:57,031,766...57,090,888
|
|
G |
Csf2ra |
colony stimulating factor 2 receptor subunit alpha |
affects methylation |
EXP |
Cannabidiol affects the methylation of CSF2RA gene |
CTD |
PMID:30521419 |
|
NCBI chr14:1,462,292...1,467,264
Ensembl chr14:1,462,358...1,467,264
|
|
G |
Csnk1e |
casein kinase 1, epsilon |
affects methylation |
EXP |
Cannabidiol affects the methylation of CSNK1E gene |
CTD |
PMID:30521419 |
|
NCBI chr 7:120,651,976...120,675,559
Ensembl chr 7:120,651,881...120,672,359
|
|
G |
Csrnp1 |
cysteine and serine rich nuclear protein 1 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of CSRNP1 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 8:128,659,883...128,673,339
Ensembl chr 8:128,659,868...128,672,284
|
|
G |
Ctsg |
cathepsin G |
increases expression |
ISO |
Cannabidiol results in increased expression of CTSG mRNA |
CTD |
PMID:21542829 |
|
NCBI chr15:35,107,333...35,113,678
Ensembl chr15:35,111,091...35,113,678
|
|
G |
Cx3cr1 |
C-X3-C motif chemokine receptor 1 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CX3CR1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 8:128,740,756...128,754,514
Ensembl chr 8:128,740,756...128,754,514
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
[Dronabinol co-treated with Cannabidiol] inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; [Dronabinol co-treated with Cannabidiol] inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 protein]; [Dronabinol co-treated with Cannabidiol] inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein]; Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 protein]; Cannabidiol inhibits the reaction [Poly I-C results in increased expression of CXCL10 mRNA]; Cannabidiol inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein] |
CTD |
PMID:32244040 |
|
NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
|
|
G |
Cxcl14 |
C-X-C motif chemokine ligand 14 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CXCL14 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr17:9,109,731...9,117,754
Ensembl chr17:9,109,731...9,117,750
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of CXCL9 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr14:17,228,832...17,233,743
Ensembl chr14:17,228,856...17,234,712
|
|
G |
Cxcr1 |
C-X-C motif chemokine receptor 1 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of CXCR1 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 9:81,466,430...81,469,299
Ensembl chr 9:81,466,332...81,469,274
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
multiple interactions increases expression |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of CXCR4 mRNA Cannabidiol results in increased expression of CXCR4 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr13:45,314,952...45,318,856
Ensembl chr13:45,314,933...45,318,878
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
decreases activity multiple interactions |
ISO |
Cannabidiol results in decreased activity of CYP19A1 protein Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of CYP19A1 mRNA] |
CTD |
PMID:31953017 |
|
NCBI chr 8:58,744,849...58,772,408
Ensembl chr 8:58,744,849...58,772,408
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
ISO |
Cannabidiol results in decreased activity of CYP1A1 protein |
CTD |
PMID:24667653 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity |
ISO |
Cannabidiol results in decreased activity of CYP1A2 protein |
CTD |
PMID:24667653 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
decreases activity |
ISO |
Cannabidiol results in decreased activity of CYP2B10 |
CTD |
PMID:8043019 |
|
NCBI chr 7:99,142,431...99,183,540
Ensembl chr 7:99,142,450...99,181,783
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
decreases activity |
ISO |
Cannabidiol results in decreased activity of CYP2B6 protein |
CTD |
PMID:24667653 |
|
NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
decreases activity |
ISO |
Cannabidiol results in decreased activity of CYP2C9 protein |
CTD |
PMID:24667653 |
|
NCBI chr 1:257,676,172...258,004,428
Ensembl chr 1:257,970,345...258,004,434
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
decreases activity |
ISO |
Cannabidiol results in decreased activity of CYP2C19 protein |
CTD |
PMID:24667653 |
|
NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
decreases activity |
ISO |
Cannabidiol results in decreased activity of CYP2D6 protein |
CTD |
PMID:24667653 |
|
NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
decreases activity increases metabolic processing multiple interactions |
ISO |
Cannabidiol results in decreased activity of CYP3A4 protein CYP3A11 protein results in increased metabolism of Cannabidiol [CYP3A11 protein results in increased metabolism of Cannabidiol] which results in increased chemical synthesis of cannabidiol hydroxyquinone |
CTD |
PMID:9778318 PMID:24667653 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
decreases activity |
ISO |
Cannabidiol results in decreased activity of CYP3A5 protein |
CTD |
PMID:24667653 |
|
NCBI chr12:19,074,288...19,114,491
Ensembl chr12:19,074,583...19,114,399
|
|
G |
Cyrib |
CYFIP related Rac1 interactor B |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CYRIB mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 7:104,514,566...104,641,875
Ensembl chr 7:104,516,391...104,556,419
|
|
G |
Cytip |
cytohesin 1 interacting protein |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CYTIP mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 3:44,150,494...44,225,723
Ensembl chr 3:44,150,992...44,177,689
|
|
G |
Dapk3 |
death-associated protein kinase 3 |
affects methylation |
EXP |
Cannabidiol affects the methylation of DAPK3 gene |
CTD |
PMID:30521419 |
|
NCBI chr 7:11,392,436...11,400,855
Ensembl chr 7:11,392,437...11,400,805
|
|
G |
Dct |
dopachrome tautomerase |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of DCT mRNA; Cannabidiol results in increased expression of DCT protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cannabidiol results in increased expression of DCT mRNA]; SB 203580 inhibits the reaction [Cannabidiol results in increased expression of DCT mRNA] |
CTD |
PMID:28601556 |
|
NCBI chr15:103,208,174...103,245,033
Ensembl chr15:103,208,258...103,244,494
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of DDIT3 mRNA [Bilirubin co-treated with Rotenone] promotes the reaction [Cannabidiol results in increased expression of DDIT3 mRNA]; Bilirubin inhibits the reaction [Cannabidiol results in increased expression of DDIT3 mRNA]; Rotenone promotes the reaction [Cannabidiol results in increased expression of DDIT3 mRNA] |
CTD |
PMID:21542829 PMID:32033040 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of DDIT4 mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of DDIT4 mRNA |
CTD |
PMID:21542829 PMID:30742662 |
|
NCBI chr20:29,509,283...29,511,382
Ensembl chr20:29,509,289...29,511,382
|
|
G |
Ddr1 |
discoidin domain receptor tyrosine kinase 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of DDR1 mRNA |
CTD |
PMID:27256343 |
|
NCBI chr20:3,553,430...3,574,959
Ensembl chr20:3,552,929...3,575,780
|
|
G |
Dgat1 |
diacylglycerol O-acyltransferase 1 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of DGAT1 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 7:117,566,363...117,576,735
Ensembl chr 7:117,566,368...117,576,737
|
|
G |
Dlg4 |
discs large MAGUK scaffold protein 4 |
affects methylation |
EXP |
Cannabidiol affects the methylation of DLG4 gene |
CTD |
PMID:30521419 |
|
NCBI chr10:56,625,845...56,655,543
Ensembl chr10:56,627,411...56,653,599
|
|
G |
Dll1 |
delta like canonical Notch ligand 1 |
multiple interactions increases expression |
ISO |
Cannabidiol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of DLL1 mRNA] Cannabidiol results in increased expression of DLL1 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 1:57,318,621...57,326,732
Ensembl chr 1:57,318,708...57,327,379
|
|
G |
Dnmt3l |
DNA methyltransferase 3 like |
increases expression |
ISO |
Cannabidiol results in increased expression of DNMT3L mRNA |
CTD |
PMID:21542829 |
|
NCBI chr20:11,344,513...11,359,090
Ensembl chr20:11,344,514...11,359,090
|
|
G |
Dok2 |
docking protein 2 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of DOK2 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr15:52,449,884...52,455,414
Ensembl chr15:52,451,161...52,456,409
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of DUSP1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr10:16,970,642...16,973,425
Ensembl chr10:16,970,626...16,973,418
|
|
G |
Dusp6 |
dual specificity phosphatase 6 |
multiple interactions |
ISO |
[Cannabidiol co-treated with MOG protein modified form] results in increased expression of DUSP6 mRNA; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of DUSP6 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 7:41,475,163...41,479,393
Ensembl chr 7:41,475,163...41,479,392
|
|
G |
E2f2 |
E2F transcription factor 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of E2F2 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 5:154,516,611...154,540,228
Ensembl chr 5:154,522,119...154,540,265
|
|
G |
E2f5 |
E2F transcription factor 5 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of E2F5 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 2:88,350,764...88,366,913
Ensembl chr 2:88,351,361...88,366,115
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
[Dronabinol co-treated with Cannabidiol] results in decreased expression of EGFR mRNA; Pertussis Toxin inhibits the reaction [[Dronabinol co-treated with Cannabidiol] results in decreased expression of EGFR mRNA] |
CTD |
PMID:32049991 |
|
NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of EIF4EBP1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr16:68,954,860...68,968,248
Ensembl chr16:68,954,875...68,968,248
|
|
G |
Eif5a |
eukaryotic translation initiation factor 5A |
decreases expression |
ISO |
Cannabidiol results in decreased expression of EIF5A mRNA |
CTD |
PMID:21542829 |
|
NCBI chr10:56,527,075...56,531,615
Ensembl chr10:56,527,085...56,531,483
|
|
G |
Eno2 |
enolase 2 |
multiple interactions |
EXP |
Cannabidiol inhibits the reaction [3-nitropropionic acid results in decreased expression of ENO2 mRNA] |
CTD |
PMID:17672854 |
|
NCBI chr 4:157,285,192...157,294,090
Ensembl chr 4:157,285,179...157,294,047
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of EPHX1 mRNA |
CTD |
PMID:27256343 |
|
NCBI chr13:99,271,390...99,300,580
Ensembl chr13:99,271,366...99,300,579
|
|
G |
Ets2 |
ETS proto-oncogene 2, transcription factor |
increases expression |
ISO |
Cannabidiol results in increased expression of ETS2 mRNA |
CTD |
PMID:27256343 |
|
NCBI chr11:36,075,709...36,092,495
Ensembl chr11:36,075,709...36,092,495
|
|
G |
Ezr |
ezrin |
affects methylation |
EXP |
Cannabidiol affects the methylation of EZR gene |
CTD |
PMID:30521419 |
|
NCBI chr 1:47,287,872...47,331,412
Ensembl chr 1:47,287,874...47,331,412
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression |
ISO |
Cannabidiol results in increased expression of F3 protein |
CTD |
PMID:27556861 |
|
NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [11-(dansylamino)undecanoic acid binds to FABP1 protein] |
CTD |
PMID:31110286 |
|
NCBI chr 4:99,063,181...99,066,957
Ensembl chr 4:99,063,181...99,066,954
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
Cannabidiol results in increased expression of FAS mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Fdps |
farnesyl diphosphate synthase |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of FDPS mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 2:188,403,595...188,413,219
Ensembl chr 2:188,392,858...188,413,219
|
|
G |
Fgf12 |
fibroblast growth factor 12 |
affects methylation |
EXP |
Cannabidiol affects the methylation of FGF12 gene |
CTD |
PMID:30521419 |
|
NCBI chr11:75,606,360...76,171,078
Ensembl chr11:75,905,443...76,168,989
|
|
G |
Fgf14 |
fibroblast growth factor 14 |
affects methylation |
EXP |
Cannabidiol affects the methylation of FGF14 gene |
CTD |
PMID:30521419 |
|
NCBI chr15:110,382,274...111,077,027
Ensembl chr15:110,385,217...110,612,681
|
|
G |
Fgfr2 |
fibroblast growth factor receptor 2 |
affects methylation |
EXP |
Cannabidiol affects the methylation of FGFR2 gene |
CTD |
PMID:30521419 |
|
NCBI chr 1:200,590,951...200,696,946
Ensembl chr 1:200,590,953...200,696,928
|
|
G |
Fgfr4 |
fibroblast growth factor receptor 4 |
affects methylation |
EXP |
Cannabidiol affects the methylation of FGFR4 gene |
CTD |
PMID:30521419 |
|
NCBI chr17:9,990,072...10,004,339
Ensembl chr17:9,990,078...10,004,321
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
decreases expression multiple interactions |
ISO |
Cannabidiol results in decreased expression of FOS mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of FOS mRNA |
CTD |
PMID:21542829 PMID:30742662 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of FOXO1 mRNA] |
CTD |
PMID:31953017 |
|
NCBI chr 2:141,451,234...141,527,016
Ensembl chr 2:141,451,234...141,527,016
|
|
G |
Fzd9 |
frizzled class receptor 9 |
affects methylation |
EXP |
Cannabidiol affects the methylation of FZD9 gene |
CTD |
PMID:30521419 |
|
NCBI chr12:24,473,981...24,476,295
Ensembl chr12:24,473,981...24,476,295
|
|
G |
Gad1 |
glutamate decarboxylase 1 |
multiple interactions |
EXP |
Cannabidiol inhibits the reaction [Poly I-C results in decreased expression of GAD1 protein] |
CTD |
PMID:31202911 |
|
NCBI chr 3:56,861,440...56,902,139
Ensembl chr 3:56,861,396...56,902,157
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases expression |
ISO |
Cannabidiol results in increased expression of GADD45A mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 4:97,782,512...97,784,814
Ensembl chr 4:97,782,512...97,784,842
|
|
G |
Gas1 |
growth arrest-specific 1 |
multiple interactions increases expression |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of GAS1 mRNA Cannabidiol results in increased expression of GAS1 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr17:4,846,116...4,849,350
Ensembl chr17:4,846,789...4,847,940
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression |
ISO |
Cannabidiol results in increased expression of GCLM mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 2:225,827,504...225,847,876
Ensembl chr 2:225,827,504...225,847,874
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression |
ISO |
Cannabidiol results in increased expression of GDF15 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr16:20,555,395...20,557,978
Ensembl chr16:20,555,395...20,557,978
|
|
G |
Gdf6 |
growth differentiation factor 6 |
affects methylation |
EXP |
Cannabidiol affects the methylation of GDF6 gene |
CTD |
PMID:30521419 |
|
NCBI chr 5:23,056,345...23,072,666
Ensembl chr 5:23,056,347...23,074,599
|
|
G |
Gfod1 |
glucose-fructose oxidoreductase domain containing 1 |
multiple interactions |
ISO |
Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of GFOD1 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr17:23,818,370...23,924,393
Ensembl chr17:23,823,632...23,923,792
|
|
G |
Gli1 |
GLI family zinc finger 1 |
affects methylation |
EXP |
Cannabidiol affects the methylation of GLI1 gene |
CTD |
PMID:30521419 |
|
NCBI chr 7:70,620,794...70,633,171
Ensembl chr 7:70,620,766...70,630,338
|
|
G |
Gnb2 |
G protein subunit beta 2 |
affects methylation |
EXP |
Cannabidiol affects the methylation of GNB2 gene |
CTD |
PMID:30521419 |
|
NCBI chr12:22,229,079...22,234,096
Ensembl chr12:22,229,079...22,234,096
|
|
G |
Gng7 |
G protein subunit gamma 7 |
affects methylation |
EXP |
Cannabidiol affects the methylation of GNG7 gene |
CTD |
PMID:30521419 |
|
NCBI chr 7:11,565,740...11,629,519
Ensembl chr 7:11,582,984...11,628,929
|
|
G |
Gpnmb |
glycoprotein nmb |
increases expression |
ISO |
Cannabidiol results in increased expression of GPNMB mRNA |
CTD |
PMID:27256343 |
|
NCBI chr 4:78,694,447...78,715,685
Ensembl chr 4:78,694,447...78,715,683
|
|
G |
Gpr183 |
G protein-coupled receptor 183 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of GPR183 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr15:108,364,701...108,376,221
Ensembl chr15:108,364,701...108,376,221
|
|
G |
Gpr83 |
G protein-coupled receptor 83 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of GPR83 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 8:13,365,583...13,376,071
Ensembl chr 8:13,365,583...13,376,070
|
|
G |
Gpt2 |
glutamic--pyruvic transaminase 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of GPT2 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr19:22,599,003...22,633,529
Ensembl chr19:22,590,881...22,632,071
|
|
G |
Gsr |
glutathione-disulfide reductase |
decreases activity |
ISO |
Cannabidiol results in decreased activity of GSR protein |
CTD |
PMID:18929579 PMID:32752303 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of GSTM1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 2:210,803,869...210,809,461
Ensembl chr 2:210,803,869...210,809,306
|
|
G |
H1f2 |
H1.2 linker histone, cluster member |
increases expression |
ISO |
Cannabidiol results in increased expression of H1F2 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr17:43,638,938...43,640,445
Ensembl chr17:43,639,749...43,640,387
|
|
G |
Hbp1 |
HMG-box transcription factor 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of HBP1 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 6:51,231,479...51,257,699
Ensembl chr 6:51,231,480...51,257,625
|
|
G |
Herpud1 |
homocysteine inducible ER protein with ubiquitin like domain 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of HERPUD1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr19:11,046,905...11,057,440
Ensembl chr19:11,046,909...11,057,254
|
|
G |
Hes2 |
hes family bHLH transcription factor 2 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of HES2 mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of HES2 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 5:169,338,097...169,339,142
Ensembl chr 5:169,338,097...169,339,142
|
|
G |
Hgf |
hepatocyte growth factor |
affects methylation |
EXP |
Cannabidiol affects the methylation of HGF gene |
CTD |
PMID:30521419 |
|
NCBI chr 4:15,435,460...15,505,377
Ensembl chr 4:15,433,295...15,505,362
|
|
G |
Hist1h2af |
histone cluster 1 H2A family member F |
increases expression |
ISO |
Cannabidiol results in increased expression of H2AC6 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr17:43,627,237...43,627,629
Ensembl chr17:43,627,237...43,627,629
|
|
G |
Hist1h2ail1 |
histone cluster 1 H2a family member I like 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of H3C6 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr17:43,814,773...43,815,183
Ensembl chr17:43,814,773...43,815,183 Ensembl chr17:43,814,773...43,815,183
|
|
G |
Hist2h2be |
histone cluster 2 H2B family member E |
increases expression |
ISO |
Cannabidiol results in increased expression of H2BC21 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 2:198,360,837...198,363,399
Ensembl chr 2:198,360,998...198,361,378
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions affects response to substance |
ISO |
Cannabidiol results in increased expression of HMOX1 mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of HMOX1 mRNA; [Rotenone co-treated with Bilirubin] inhibits the reaction [Cannabidiol results in increased expression of HMOX1 mRNA]; Bilirubin inhibits the reaction [Cannabidiol results in increased expression of HMOX1 mRNA]; Rotenone promotes the reaction [Cannabidiol results in increased expression of HMOX1 mRNA] Cannabidiol results in increased expression of HMOX1 mRNA; Cannabidiol results in increased expression of HMOX1 protein HMOX1 protein affects the susceptibility to Cannabidiol [bafilomycin A1 co-treated with tin protoporphyrin IX] promotes the reaction [Cannabidiol results in increased expression of HMOX1 protein]; Acetylcysteine inhibits the reaction [Cannabidiol results in increased expression of HMOX1 protein]; iodopravadoline promotes the reaction [Cannabidiol results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [Cannabidiol results in increased expression of HMOX1 protein]; tin protoporphyrin IX promotes the reaction [Cannabidiol results in increased expression of HMOX1 protein] |
CTD |
PMID:21542829 PMID:30349652 PMID:30742662 PMID:32033040 PMID:32708634 PMID:33076330 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hnf1a |
HNF1 homeobox A |
affects methylation |
EXP |
Cannabidiol affects the methylation of HNF1A gene |
CTD |
PMID:30521419 |
|
NCBI chr12:47,407,811...47,433,342
Ensembl chr12:47,407,811...47,433,342
|
|
G |
Hp |
haptoglobin |
increases expression |
ISO |
Cannabidiol results in increased expression of HP mRNA |
CTD |
PMID:21542829 |
|
NCBI chr19:42,096,255...42,100,805
Ensembl chr19:42,097,995...42,100,804
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
[Cannabidiol co-treated with Rotenone] results in increased expression of HSPA5 mRNA; Bilirubin inhibits the reaction [[Cannabidiol co-treated with Rotenone] results in increased expression of HSPA5 mRNA] |
CTD |
PMID:32033040 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Htatip2 |
HIV-1 Tat interactive protein 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of HTATIP2 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:105,094,272...105,109,459
Ensembl chr 1:105,094,411...105,109,461
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions increases expression |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cannabidiol results in increased expression of ICAM1 mRNA]; AM 251 inhibits the reaction [Cannabidiol results in increased expression of ICAM1 mRNA]; capsazepine inhibits the reaction [Cannabidiol results in increased expression of ICAM1 mRNA]; ICAM1 mutant form inhibits the reaction [Cannabidiol results in increased expression of TIMP1 protein]; iodopravadoline inhibits the reaction [Cannabidiol results in increased expression of ICAM1 mRNA] Cannabidiol results in increased expression of ICAM1 mRNA; Cannabidiol results in increased expression of ICAM1 protein |
CTD |
PMID:22198381 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Id1 |
inhibitor of DNA binding 1, HLH protein |
decreases expression affects response to substance |
ISO |
Cannabidiol results in decreased expression of ID1 mRNA; Cannabidiol results in decreased expression of ID1 protein ID1 protein affects the susceptibility to Cannabidiol |
CTD |
PMID:21542829 PMID:24910342 |
|
NCBI chr 3:148,214,623...148,216,715
Ensembl chr 3:148,215,540...148,216,718
|
|
G |
Ido1 |
indoleamine 2,3-dioxygenase 1 |
multiple interactions |
ISO |
AM 281 promotes the reaction [Cannabidiol inhibits the reaction [Plant Preparations results in increased activity of IDO1 protein]]; Cannabidiol inhibits the reaction [[Plant Preparations results in increased activity of IDO1 protein] which results in increased abundance of Neopterin]; Cannabidiol inhibits the reaction [Plant Preparations results in increased activity of IDO1 protein]; Cannabidiol inhibits the reaction [Plant Preparations results in increased expression of IDO1 mRNA]; iodopravadoline promotes the reaction [Cannabidiol inhibits the reaction [Plant Preparations results in increased activity of IDO1 protein]] |
CTD |
PMID:19167098 |
|
NCBI chr16:72,216,326...72,228,098
Ensembl chr16:72,216,326...72,228,098
|
|
G |
Ier3 |
immediate early response 3 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of IER3 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr20:3,438,798...3,440,002
Ensembl chr20:3,438,798...3,440,769
|
|
G |
Ifnb1 |
interferon beta 1 |
multiple interactions increases expression |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of IFNB1 mRNA; Cannabidiol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IFNB1 mRNA]; Cannabidiol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IFNB1 protein] [Dronabinol co-treated with Cannabidiol] inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 protein]; [Dronabinol co-treated with Cannabidiol] inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 protein]; Cannabidiol inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA] Cannabidiol results in increased expression of IFNB1 mRNA |
CTD |
PMID:19910459 PMID:21542829 PMID:30742662 PMID:32244040 |
|
NCBI chr 5:106,865,192...106,865,746
Ensembl chr 5:106,865,192...106,865,746
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Cannabidiol co-treated with TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA; Cannabidiol affects the reaction [Plant Preparations results in increased secretion of IFNG protein]; Cannabidiol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in decreased expression of TRPV1 mRNA]; Cannabidiol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA]; Cannabidiol inhibits the reaction [Plant Preparations results in increased expression of IFNG mRNA] |
CTD |
PMID:19167098 PMID:31054246 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Ifngr1 |
interferon gamma receptor 1 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of IFNGR1 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 1:15,062,380...15,080,815
Ensembl chr 1:15,062,432...15,080,907
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA] |
CTD |
PMID:31953017 |
|
NCBI chr14:87,448,716...87,453,783
Ensembl chr14:87,448,692...87,453,785
|
|
G |
Igfbp4 |
insulin-like growth factor binding protein 4 |
decreases expression multiple interactions |
ISO |
Cannabidiol results in decreased expression of IGFBP4 mRNA Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of IGFBP4 mRNA] |
CTD |
PMID:21542829 PMID:27256343 |
|
NCBI chr10:86,950,555...86,962,563
Ensembl chr10:86,950,557...86,962,578
|
|
G |
Il12a |
interleukin 12A |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of IL12A mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 2:165,076,945...165,083,996
Ensembl chr 2:165,076,607...165,084,318
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions decreases expression |
ISO EXP |
Cannabidiol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B mRNA]; Cannabidiol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL1B protein]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of IL1B mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased secretion of IL1B protein] Cannabidiol inhibits the reaction [Hydrogen Peroxide results in increased expression of IL1B protein]; Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein] Cannabidiol results in decreased expression of IL1B mRNA |
CTD |
PMID:19910459 PMID:21492165 PMID:21542829 PMID:27256343 PMID:27430346 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il2 |
interleukin 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of IL2 protein |
CTD |
PMID:11809870 |
|
NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
|
|
G |
Il3 |
interleukin 3 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of IL3 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased secretion of IL3 protein] |
CTD |
PMID:27256343 |
|
NCBI chr10:39,620,535...39,622,973
Ensembl chr10:39,620,563...39,622,973
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression |
ISO EXP |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of IL6 mRNA; [Rotenone co-treated with Bilirubin] inhibits the reaction [Cannabidiol results in increased expression of IL6 mRNA]; Bilirubin inhibits the reaction [Cannabidiol results in increased expression of IL6 mRNA]; Cannabidiol inhibits the reaction [APP alternative form results in increased expression of IL6 mRNA]; Cannabidiol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL6 protein]; Rotenone inhibits the reaction [Cannabidiol results in increased expression of IL6 mRNA] Cannabidiol inhibits the reaction [Hydrogen Peroxide results in increased expression of IL6 protein]; Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein] |
CTD |
PMID:19910459 PMID:21350020 PMID:21492165 PMID:27430346 PMID:30742662 PMID:32033040 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Il6r |
interleukin 6 receptor |
decreases expression |
ISO |
Cannabidiol results in decreased expression of IL6RA mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 2:189,196,180...189,255,987
Ensembl chr 2:189,205,701...189,254,628
|
|
G |
Inpp5d |
inositol polyphosphate-5-phosphatase D |
decreases expression |
ISO |
Cannabidiol results in decreased expression of INPP5D mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 9:94,745,220...94,850,778
Ensembl chr 9:94,745,217...94,850,771
|
|
G |
Irak1 |
interleukin-1 receptor-associated kinase 1 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased degradation of IRAK1 protein] |
CTD |
PMID:19910459 |
|
NCBI chr X:156,716,469...156,726,367
Ensembl chr X:156,716,604...156,725,977
|
|
G |
Irak3 |
interleukin-1 receptor-associated kinase 3 |
multiple interactions |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of IRAK3 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 7:64,922,830...64,982,224
Ensembl chr 7:64,923,615...64,982,281
|
|
G |
Irf3 |
interferon regulatory factor 3 |
multiple interactions |
ISO |
[Dronabinol co-treated with Cannabidiol] inhibits the reaction [Poly I-C affects the localization of IRF3 protein]; Cannabidiol inhibits the reaction [Poly I-C affects the localization of IRF3 protein] |
CTD |
PMID:32244040 |
|
NCBI chr 1:100,992,244...100,997,202
Ensembl chr 1:100,992,405...100,997,198
|
|
G |
Irf4 |
interferon regulatory factor 4 |
multiple interactions increases expression |
ISO |
Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of IRF4 mRNA] Cannabidiol results in increased expression of IRF4 mRNA |
CTD |
PMID:27256343 |
|
NCBI chr17:34,886,746...34,905,191
Ensembl chr17:34,886,739...34,905,117
|
|
G |
Itgb3 |
integrin subunit beta 3 |
affects methylation |
EXP |
Cannabidiol affects the methylation of ITGB3 gene |
CTD |
PMID:30521419 |
|
NCBI chr10:92,667,869...92,783,413
Ensembl chr10:92,667,869...92,783,410
|
|
G |
Jak3 |
Janus kinase 3 |
affects methylation |
EXP |
Cannabidiol affects the methylation of JAK3 gene |
CTD |
PMID:30521419 |
|
NCBI chr16:20,107,471...20,120,678
Ensembl chr16:20,109,200...20,120,668
|
|
G |
Jaml |
junction adhesion molecule like |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of JAML mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 8:49,378,644...49,408,894
Ensembl chr 8:49,378,644...49,410,088
|
|
G |
Jdp2 |
Jun dimerization protein 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of JDP2 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 6:109,464,910...109,505,591
Ensembl chr 6:109,466,060...109,505,161
|
|
G |
Kctd12 |
potassium channel tetramerization domain containing 12 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of KCTD12 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr15:87,384,632...87,390,627
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
decreases expression |
EXP |
Cannabidiol results in decreased expression of KRAS mRNA |
CTD |
PMID:32553926 |
|
NCBI chr 4:179,482,562...179,515,483
Ensembl chr 4:179,486,105...179,515,558
|
|
G |
Lamc1 |
laminin subunit gamma 1 |
affects methylation |
EXP |
Cannabidiol affects the methylation of LAMC1 gene |
CTD |
PMID:30521419 |
|
NCBI chr13:70,656,727...70,783,515
Ensembl chr13:70,658,707...70,783,515
|
|
G |
Lcn2 |
lipocalin 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of LCN2 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 3:11,414,189...11,417,534
Ensembl chr 3:11,414,186...11,417,546
|
|
G |
Limk2 |
LIM domain kinase 2 |
affects methylation |
EXP |
Cannabidiol affects the methylation of LIMK2 gene |
CTD |
PMID:30521419 |
|
NCBI chr14:83,564,048...83,641,996
Ensembl chr14:83,573,928...83,641,892
|
|
G |
Llgl1 |
LLGL scribble cell polarity complex component 1 |
affects methylation |
EXP |
Cannabidiol affects the methylation of LLGL1 gene |
CTD |
PMID:30521419 |
|
NCBI chr10:46,940,873...46,955,524
Ensembl chr10:46,940,965...46,954,674
|
|
G |
LOC102553180 |
protocadherin alpha-1-like |
increases expression |
ISO |
Cannabidiol results in increased expression of PCDHA1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr18:29,824,891...29,839,850
|
|
G |
Lpin1 |
lipin 1 |
multiple interactions increases expression |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of LPIN1 mRNA Cannabidiol results in increased expression of LPIN1 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 6:41,796,214...41,905,149
Ensembl chr 6:41,799,749...41,870,046
|
|
G |
Ly86 |
lymphocyte antigen 86 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of LY86 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr17:28,104,535...28,191,447
Ensembl chr17:28,104,589...28,191,436
|
|
G |
Mafb |
MAF bZIP transcription factor B |
decreases expression multiple interactions |
ISO |
Cannabidiol results in decreased expression of MAFB mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of MAFB mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 3:156,338,993...156,340,913
Ensembl chr 3:156,339,004...156,340,913
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
affects methylation |
EXP |
Cannabidiol affects the methylation of MAP2K1 gene |
CTD |
PMID:30521419 |
|
NCBI chr 8:69,134,218...69,722,573
Ensembl chr 8:69,134,223...69,164,758
|
|
G |
Map2k6 |
mitogen-activated protein kinase kinase 6 |
affects methylation |
EXP |
Cannabidiol affects the methylation of MAP2K6 gene |
CTD |
PMID:30521419 |
|
NCBI chr10:98,707,160...98,823,054
Ensembl chr10:98,706,960...98,823,287
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation |
ISO |
Cannabidiol results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:28601556 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
decreases expression |
EXP |
Cannabidiol results in decreased expression of MAPK14 mRNA |
CTD |
PMID:32553926 |
|
NCBI chr20:5,933,290...5,995,137
Ensembl chr20:5,933,303...5,995,137
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation |
ISO |
Cannabidiol results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:28601556 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapt |
microtubule-associated protein tau |
affects methylation |
EXP |
Cannabidiol affects the methylation of MAPT gene |
CTD |
PMID:30521419 |
|
NCBI chr10:92,289,002...92,386,517
Ensembl chr10:92,288,910...92,386,517
|
|
G |
Mat2a |
methionine adenosyltransferase 2A |
decreases expression |
ISO |
Cannabidiol results in decreased expression of MAT2A mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 4:100,297,478...100,303,047
Ensembl chr 4:100,296,075...100,303,080
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
multiple interactions increases expression |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of MDM2 mRNA Cannabidiol results in increased expression of MDM2 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 7:60,719,060...60,743,618
Ensembl chr 7:60,719,066...60,743,328
|
|
G |
Mecom |
MDS1 and EVI1 complex locus |
affects methylation |
EXP |
Cannabidiol affects the methylation of MECOM gene |
CTD |
PMID:30521419 |
|
NCBI chr 2:117,396,084...117,993,604
Ensembl chr 2:117,396,007...117,454,769
|
|
G |
Mef2b |
myocyte enhancer factor 2B |
increases expression |
ISO |
Cannabidiol results in increased expression of MEF2B mRNA |
CTD |
PMID:21542829 |
|
NCBI chr16:21,001,204...21,017,651
Ensembl chr16:21,001,206...21,017,163
|
|
G |
Mef2c |
myocyte enhancer factor 2C |
decreases expression |
ISO |
Cannabidiol results in decreased expression of MEF2C mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 2:11,658,534...11,822,788
Ensembl chr 2:11,658,568...11,822,787
|
|
G |
Mir145 |
microRNA 145 |
multiple interactions |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of MIR145A mRNA |
CTD |
PMID:30742662 |
|
NCBI chr18:56,969,907...56,969,994
Ensembl chr18:56,969,907...56,969,994
|
|
G |
Mir146a |
microRNA 146a |
multiple interactions decreases expression |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of MIR146 mRNA; Cannabidiol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of MIR146 mRNA] Cannabidiol results in decreased expression of MIR146 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr10:28,962,476...28,962,570
Ensembl chr10:28,962,476...28,962,570
|
|
G |
Mir155 |
microRNA 155 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of MIR155 mRNA] |
CTD |
PMID:30742662 |
|
NCBI chr11:24,176,603...24,176,667
Ensembl chr11:24,176,603...24,176,667
|
|
G |
Mir181b1 |
microRNA 181b-1 |
increases expression |
ISO |
Cannabidiol results in increased expression of MIR181B-1 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr13:54,952,903...54,953,012
Ensembl chr13:54,952,903...54,953,012
|
|
G |
Mir21 |
microRNA 21 |
multiple interactions |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of MIR21A mRNA |
CTD |
PMID:30742662 |
|
NCBI chr10:73,902,210...73,902,301
Ensembl chr10:73,902,210...73,902,301
|
|
G |
Mir221 |
microRNA 221 |
multiple interactions |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of MIR221 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr X:3,684,480...3,684,588
Ensembl chr X:3,684,480...3,684,588
|
|
G |
Mir222 |
microRNA 222 |
multiple interactions |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of MIR222 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr X:3,683,919...3,684,021
Ensembl chr X:3,683,919...3,684,021
|
|
G |
Mir25 |
microRNA 25 |
multiple interactions |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of MIR25 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr12:19,307,340...19,307,423
Ensembl chr12:19,307,340...19,307,423
|
|
G |
Mir34a |
microRNA 34a |
multiple interactions increases expression |
ISO |
[Cannabidiol co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MIR34A mRNA Cannabidiol results in increased expression of MIR34A mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 5:167,092,491...167,092,592
Ensembl chr 5:167,092,491...167,092,592
|
|
G |
Mir449a |
microRNA 449a |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of MIR449A mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of MIR449A mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 2:44,897,601...44,897,691
Ensembl chr 2:44,897,601...44,897,691
|
|
G |
Mitf |
melanocyte inducing transcription factor |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of MITF mRNA; Cannabidiol results in increased expression of MITF protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cannabidiol results in increased expression of MITF mRNA]; SB 203580 inhibits the reaction [Cannabidiol results in increased expression of MITF mRNA] |
CTD |
PMID:28601556 |
|
NCBI chr 4:130,172,484...130,425,496
Ensembl chr 4:130,172,727...130,425,532
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of MKI67 protein |
CTD |
PMID:24910342 |
|
NCBI chr 1:207,993,895...208,020,454
Ensembl chr 1:207,993,895...208,020,454
|
|
G |
Mmp23 |
matrix metallopeptidase 23 |
increases expression |
ISO |
Cannabidiol results in increased expression of MMP23 mRNA |
CTD |
PMID:21542829 PMID:22178458 |
|
NCBI chr 5:173,078,811...173,082,834
Ensembl chr 5:173,078,590...173,081,839
|
|
G |
Mog |
myelin oligodendrocyte glycoprotein |
multiple interactions |
ISO |
[Cannabidiol co-treated with MOG protein modified form] results in increased expression of DUSP6 mRNA; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of ATF3 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of CDK5R1 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of CREM mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of CSRNP1 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of CXCL9 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of CXCR1 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of DGAT1 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of FDPS mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of GPR83 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of IER3 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of IFNGR1 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of IGFBP4 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of IL12A mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of IL1B mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of IL3 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of JAML mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of NR4A3 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of SPHK1 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of TNFRSF18 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of TNFRSF9 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of TNFSF11 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of TNFSF14 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of TUBB2B mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of VPS37B mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of XCL1 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased secretion of IL1B protein]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased secretion of IL3 protein]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of BTLA mRNA]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of CD69 mRNA]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of CMPK2 mRNA]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of DUSP6 mRNA]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of GBP11 mRNA]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of GFOD1 mRNA]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of IRF4 mRNA]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of MX2 mRNA]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of PPIC mRNA]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of RSAD2 mRNA]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of TAGAP mRNA]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of TNFSF8 mRNA]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of TRIM30A mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr20:2,003,871...2,014,284
Ensembl chr20:2,004,052...2,014,286
|
|
G |
Mr1 |
major histocompatibility complex, class I-related |
multiple interactions increases expression |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of MR1 mRNA Cannabidiol results in increased expression of MR1 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr13:72,771,992...72,789,861
Ensembl chr13:72,771,984...72,789,841
|
|
G |
Mt1 |
metallothionein 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of MT1 mRNA |
CTD |
PMID:27256343 |
|
NCBI chr19:11,301,991...11,303,007
Ensembl chr17:78,793,336...78,793,724
|
|
G |
Mt2A |
metallothionein 2A |
increases expression |
ISO |
Cannabidiol results in increased expression of MT2 mRNA |
CTD |
PMID:21542829 PMID:22178458 PMID:27256343 |
|
NCBI chr19:11,307,966...11,308,740
Ensembl chr19:11,307,967...11,308,740
|
|
G |
Mx2 |
MX dynamin like GTPase 2 |
multiple interactions |
ISO |
Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of MX2 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr11:38,035,306...38,066,185
Ensembl chr11:38,035,450...38,059,950
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
affects methylation |
EXP |
Cannabidiol affects the methylation of MYC gene |
CTD |
PMID:30521419 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Nckap1l |
NCK associated protein 1 like |
affects methylation |
EXP |
Cannabidiol affects the methylation of NCKAP1L gene |
CTD |
PMID:30521419 |
|
NCBI chr 7:145,068,239...145,113,507
Ensembl chr 7:145,068,286...145,113,507
|
|
G |
Ndrg1 |
N-myc downstream regulated 1 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of NDRG1 mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of NDRG1 mRNA |
CTD |
PMID:21542829 PMID:22178458 PMID:30742662 |
|
NCBI chr 7:107,734,326...107,775,701
Ensembl chr 7:107,734,323...107,775,714
|
|
G |
Neurl1 |
neuralized E3 ubiquitin protein ligase 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of NEURL1A mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:266,953,006...267,038,879
Ensembl chr 1:266,952,561...267,038,883
|
|
G |
Nfam1 |
NFAT activating protein with ITAM motif 1 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of NFAM1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 7:123,856,718...123,893,790
Ensembl chr 7:123,856,567...123,892,429
|
|
G |
Nfatc2 |
nuclear factor of activated T-cells 2 |
decreases expression multiple interactions |
ISO |
Cannabidiol results in decreased expression of NFATC2 mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of NFATC2 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 3:165,241,750...165,374,644
Ensembl chr 3:165,245,238...165,360,292
|
|
G |
Nfe2l1 |
nuclear factor, erythroid 2-like 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of NFE2L1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr10:84,686,762...84,699,313
Ensembl chr10:84,682,460...84,698,886
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of NFE2L2 protein NFE2L2 protein affects the reaction [Cannabidiol results in increased expression of HMOX1 protein] |
CTD |
PMID:32708634 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of NFKB1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nfkbib |
NFKB inhibitor beta |
increases expression |
ISO |
Cannabidiol results in increased expression of NFKBIB mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:86,941,073...86,948,845
Ensembl chr 1:86,941,074...86,948,845
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression multiple interactions |
ISO EXP |
Cannabidiol results in increased expression of NOS2 mRNA Cannabidiol inhibits the reaction [Hydrogen Peroxide results in increased expression of NOS2 protein] |
CTD |
PMID:27430346 PMID:30742662 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of NQO1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Nr4a3 |
nuclear receptor subfamily 4, group A, member 3 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of NR4A3 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 5:63,781,801...63,822,890
Ensembl chr 5:63,781,801...63,821,637
|
|
G |
Ntrk2 |
neurotrophic receptor tyrosine kinase 2 |
affects methylation |
EXP |
Cannabidiol affects the methylation of NTRK2 gene |
CTD |
PMID:30521419 |
|
NCBI chr17:5,934,651...6,245,778
Ensembl chr17:5,933,729...6,244,676
|
|
G |
Nupr1 |
nuclear protein 1, transcriptional regulator |
increases expression |
ISO |
Cannabidiol results in increased expression of NUPR1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:194,767,484...194,769,519
Ensembl chr 1:194,767,474...194,769,524
|
|
G |
Oprd1 |
opioid receptor, delta 1 |
multiple interactions |
EXP |
Cannabidiol inhibits the reaction [naltrindole binds to and results in decreased activity of OPRD1 protein] |
CTD |
PMID:16489449 |
|
NCBI chr 5:150,288,126...150,323,063
Ensembl chr 5:150,288,126...150,323,063
|
|
G |
Oprm1 |
opioid receptor, mu 1 |
multiple interactions |
EXP |
Cannabidiol promotes the reaction [Naloxone inhibits the reaction [Enkephalin, Ala(2)-MePhe(4)-Gly(5)- binds to and results in increased activity of OPRM1 protein]] |
CTD |
PMID:16489449 |
|
NCBI chr 1:43,454,803...43,704,948
Ensembl chr 1:43,454,803...43,704,948
|
|
G |
Pax8 |
paired box 8 |
affects methylation |
EXP |
Cannabidiol affects the methylation of PAX8 gene |
CTD |
PMID:30521419 |
|
NCBI chr 3:1,527,316...1,586,019
Ensembl chr 3:1,527,279...1,584,946
|
|
G |
Pcdha1 |
protocadherin alpha 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of PCDHA1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr18:29,951,094...30,215,896
|
|
G |
Pcdha11 |
protocadherin alpha 11 |
increases expression |
ISO |
Cannabidiol results in increased expression of PCDHA11 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr18:30,017,918...30,215,896
Ensembl chr18:29,987,206...30,215,897
|
|
G |
Pdx1 |
pancreatic and duodenal homeobox 1 |
increases expression |
EXP |
Cannabidiol results in increased expression of PDX1 protein |
CTD |
PMID:32553926 |
|
NCBI chr12:9,496,044...9,501,211
Ensembl chr12:9,496,044...9,501,213
|
|
G |
Penk |
proenkephalin |
multiple interactions |
EXP |
Cannabidiol inhibits the reaction [3-nitropropionic acid results in decreased expression of PENK mRNA] |
CTD |
PMID:17672854 |
|
NCBI chr 5:17,056,412...17,061,762
Ensembl chr 5:17,056,419...17,061,837
|
|
G |
Pfn2 |
profilin 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of PFN2 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 2:147,953,858...147,959,692
Ensembl chr 2:147,955,196...148,050,438
|
|
G |
Pip5k1c |
phosphatidylinositol-4-phosphate 5-kinase type 1 gamma |
affects methylation |
EXP |
Cannabidiol affects the methylation of PIP5K1C gene |
CTD |
PMID:30521419 |
|
NCBI chr 7:11,267,207...11,294,291
Ensembl chr 7:11,267,218...11,294,249
|
|
G |
Pitpnm2 |
phosphatidylinositol transfer protein, membrane-associated 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of PITPNM2 mRNA |
CTD |
PMID:27256343 |
|
NCBI chr12:37,805,332...37,903,856
Ensembl chr12:37,805,332...37,903,855
|
|
G |
Plin2 |
perilipin 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of PLIN2 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 5:104,984,413...105,010,863
Ensembl chr 5:104,984,414...105,010,857
|
|
G |
Plk2 |
polo-like kinase 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of PLK2 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 2:41,911,143...41,916,901
Ensembl chr 2:41,911,131...41,916,901
|
|
G |
Plpp3 |
phospholipid phosphatase 3 |
increases expression |
ISO |
Cannabidiol results in increased expression of PLPP3 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 5:124,690,214...124,765,499
Ensembl chr 5:124,690,214...124,765,498
|
|
G |
Polr1g |
RNA polymerase I subunit G |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CD3EAP mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:80,267,725...80,271,001
Ensembl chr 1:80,267,725...80,271,001
|
|
G |
Pomgnt2 |
protein O-linked mannose N-acetylglucosaminyltransferase 2 (beta 1,4-) |
decreases expression |
ISO |
Cannabidiol results in decreased expression of POMGNT2 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 8:130,615,482...130,631,144
Ensembl chr 8:130,615,711...130,617,833
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
affects methylation |
EXP |
Cannabidiol affects the methylation of POU5F1 gene |
CTD |
PMID:30521419 |
|
NCBI chr20:3,747,231...3,751,994
Ensembl chr20:3,747,221...3,751,994
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
affects methylation |
EXP |
Cannabidiol affects the methylation of PPARD gene |
CTD |
PMID:30521419 |
|
NCBI chr20:7,818,289...7,883,482
Ensembl chr20:7,818,289...7,885,333
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression multiple interactions affects binding |
ISO EXP |
Cannabidiol results in increased expression of PPARG mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of PPARG mRNA Cannabidiol binds to PPARG protein Cannabidiol results in increased expression of and affects the localization of PPARG protein; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Cannabidiol affects the localization of PPARG protein] |
CTD |
PMID:19285060 PMID:23220503 PMID:30742662 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ppic |
peptidylprolyl isomerase C |
multiple interactions |
ISO |
Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of PPIC mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr18:48,372,039...48,384,645
Ensembl chr18:48,372,041...48,384,645
|
|
G |
Ppp1cc |
protein phosphatase 1 catalytic subunit gamma |
affects methylation |
EXP |
Cannabidiol affects the methylation of PPP1CC gene |
CTD |
PMID:30521419 |
|
NCBI chr12:39,864,302...39,882,030
Ensembl chr12:39,864,295...39,882,030
|
|
G |
Ppp1r15a |
protein phosphatase 1, regulatory subunit 15A |
increases expression |
ISO |
Cannabidiol results in increased expression of PPP1R15A mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:101,511,899...101,515,043
Ensembl chr 1:101,511,901...101,514,974
|
|
G |
Prkaca |
protein kinase cAMP-activated catalytic subunit alpha |
affects methylation |
EXP |
Cannabidiol affects the methylation of PRKACA gene |
CTD |
PMID:30521419 |
|
NCBI chr19:25,095,089...25,118,869
Ensembl chr19:25,095,089...25,118,860
|
|
G |
Prl |
prolactin |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of PRL mRNA]; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased secretion of PRL protein] |
CTD |
PMID:31154070 PMID:31953017 |
|
NCBI chr17:39,814,236...39,824,299
Ensembl chr17:39,814,244...39,824,299
|
|
G |
Ptch1 |
patched 1 |
affects methylation |
EXP |
Cannabidiol affects the methylation of PTCH1 gene |
CTD |
PMID:30521419 |
|
NCBI chr17:1,032,242...1,085,885
Ensembl chr17:1,029,048...1,093,873
|
|
G |
Ptgir |
prostaglandin I2 receptor |
increases expression |
ISO |
Cannabidiol results in increased expression of PTGIR mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:78,833,449...78,835,832
Ensembl chr 1:78,833,157...78,837,623
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
ISO EXP |
Cannabidiol results in increased expression of PTGS2 mRNA; Cannabidiol results in increased expression of PTGS2 protein Cannabidiol inhibits the reaction [Hydrogen Peroxide results in increased expression of PTGS2 mRNA] |
CTD |
PMID:23220503 PMID:27430346 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Ptpn14 |
protein tyrosine phosphatase, non-receptor type 14 |
increases expression |
ISO |
Cannabidiol results in increased expression of PTPN14 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr13:108,689,916...108,841,593
Ensembl chr13:108,696,336...108,841,511
|
|
G |
Ptprj |
protein tyrosine phosphatase, receptor type, J |
decreases expression |
ISO |
Cannabidiol results in decreased expression of PTPRJ mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 3:79,233,519...79,390,956
Ensembl chr 3:79,233,525...79,390,956
|
|
G |
Pvalb |
parvalbumin |
multiple interactions increases expression |
EXP |
[Poly I-C co-treated with Cannabidiol] results in increased expression of PVALB protein Cannabidiol results in increased expression of PVALB protein |
CTD |
PMID:31202911 PMID:31326506 |
|
NCBI chr 7:119,428,657...119,443,674
Ensembl chr 7:119,429,019...119,441,487
|
|
G |
Rab3il1 |
RAB3A interacting protein-like 1 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of RAB3IL1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:226,077,182...226,084,830
Ensembl chr 1:226,077,120...226,084,830
|
|
G |
Rasgrp1 |
RAS guanyl releasing protein 1 |
affects methylation |
EXP |
Cannabidiol affects the methylation of RASGRP1 gene |
CTD |
PMID:30521419 |
|
NCBI chr 3:108,984,029...109,044,420
Ensembl chr 3:108,984,029...109,044,420
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of RELA mRNA; Cannabidiol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of RELA protein] |
CTD |
PMID:19910459 PMID:30742662 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Relb |
RELB proto-oncogene, NF-kB subunit |
increases expression |
ISO |
Cannabidiol results in increased expression of RELB mRNA |
CTD |
PMID:21542829 PMID:30742662 |
|
NCBI chr 1:80,517,081...80,545,019
Ensembl chr 1:80,517,411...80,544,825
|
|
G |
Rin2 |
Ras and Rab interactor 2 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of RIN2 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 3:139,871,330...140,087,679
Ensembl chr 3:139,894,331...140,087,678
|
|
G |
Rora |
RAR-related orphan receptor A |
multiple interactions increases expression |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of RORA mRNA Cannabidiol results in increased expression of RORA mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 8:75,515,886...75,616,477
Ensembl chr 8:75,516,904...75,607,212
|
|
G |
Rps6 |
ribosomal protein S6 |
decreases phosphorylation |
ISO |
Cannabidiol results in decreased phosphorylation of RPS6 protein |
CTD |
PMID:28392768 |
|
NCBI chr 5:105,197,821...105,200,681
Ensembl chr 5:105,197,857...105,200,148
|
|
G |
Rsad2 |
radical S-adenosyl methionine domain containing 2 |
multiple interactions increases expression |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of RSAD2 mRNA; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of RSAD2 mRNA] Cannabidiol results in increased expression of RSAD2 mRNA |
CTD |
PMID:27256343 PMID:30742662 |
|
NCBI chr 6:45,655,947...45,669,083
Ensembl chr 6:45,655,954...45,669,148
|
|
G |
S1pr1 |
sphingosine-1-phosphate receptor 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of S1PR1 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 2:218,654,406...218,658,761
Ensembl chr 2:218,654,554...218,658,761
|
|
G |
Sars1 |
seryl-tRNA synthetase 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of SARS mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 2:211,219,743...211,235,475
Ensembl chr 2:211,219,750...211,235,467
|
|
G |
Scin |
scinderin |
affects methylation |
EXP |
Cannabidiol affects the methylation of SCIN gene |
CTD |
PMID:30521419 |
|
NCBI chr 6:59,975,375...60,055,075
Ensembl chr 6:59,976,003...60,054,279
|
|
G |
Serpine1 |
serpin family E member 1 |
decreases expression increases response to substance decreases secretion multiple interactions |
ISO |
Cannabidiol results in decreased expression of SERPINE1 mRNA SERPINE1 protein results in increased susceptibility to Cannabidiol Cannabidiol results in decreased secretion of SERPINE1 protein CNR1 protein promotes the reaction [Cannabidiol results in decreased secretion of SERPINE1 protein]; CNR2 protein promotes the reaction [Cannabidiol results in decreased secretion of SERPINE1 protein]; TRPV1 protein promotes the reaction [Cannabidiol results in decreased secretion of SERPINE1 protein] |
CTD |
PMID:20668920 |
|
NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
|
|
G |
Sfxn4 |
sideroflexin 4 |
increases expression |
ISO |
Cannabidiol results in increased expression of SFXN4 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:282,213,610...282,236,851
Ensembl chr 1:282,213,675...282,235,974
|
|
G |
Slc1a4 |
solute carrier family 1 member 4 |
increases expression |
ISO |
Cannabidiol results in increased expression of SLC1A4 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr14:104,582,884...104,612,417
Ensembl chr14:104,581,190...104,612,597
|
|
G |
Slc25a22 |
solute carrier family 25 member 22 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of SLC25A22 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:214,410,388...214,418,236
Ensembl chr 1:214,410,417...214,414,897
|
|
G |
Slc2a6 |
solute carrier family 2 member 6 |
increases expression |
ISO |
Cannabidiol results in increased expression of SLC2A6 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 3:5,567,729...5,575,144
Ensembl chr 3:5,568,321...5,575,136
|
|
G |
Slc30a1 |
solute carrier family 30 member 1 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of SLC30A1 mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of SLC30A1 mRNA |
CTD |
PMID:21542829 PMID:22178458 PMID:27256343 PMID:30742662 |
|
NCBI chr13:110,677,810...110,681,683
Ensembl chr13:110,677,810...110,681,683
|
|
G |
Slc39a10 |
solute carrier family 39 member 10 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of SLC39A10 mRNA |
CTD |
PMID:21542829 PMID:22178458 |
|
NCBI chr 9:59,947,562...60,070,549
Ensembl chr 9:60,021,534...60,070,552
|
|
G |
Slc39a4 |
solute carrier family 39 member 4 |
increases expression |
ISO |
Cannabidiol results in increased expression of SLC39A4 mRNA |
CTD |
PMID:21542829 PMID:22178458 |
|
NCBI chr 7:117,675,718...117,682,586
Ensembl chr 7:117,675,720...117,680,004
|
|
G |
Slc3a2 |
solute carrier family 3 member 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of SLC3A2 mRNA |
CTD |
PMID:21542829 PMID:27256343 |
|
NCBI chr 1:224,906,566...224,921,029
Ensembl chr 1:224,906,554...224,921,092
|
|
G |
Slc40a1 |
solute carrier family 40 member 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of SLC40A1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 9:52,819,451...52,830,461
Ensembl chr 9:52,894,365...52,912,293
|
|
G |
Slc5a6 |
solute carrier family 5 member 6 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of SLC5A6 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 6:26,685,823...26,697,110
Ensembl chr 6:26,686,033...26,697,116
|
|
G |
Slc6a9 |
solute carrier family 6 member 9 |
increases expression |
ISO |
Cannabidiol results in increased expression of SLC6A9 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 5:136,669,674...136,703,702
Ensembl chr 5:136,669,674...136,703,697
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of SLC7A11 mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of SLC7A11 mRNA |
CTD |
PMID:21542829 PMID:30742662 |
|
NCBI chr 2:139,453,774...139,528,479
Ensembl chr 2:139,453,774...139,528,162
|
|
G |
Sned1 |
sushi, nidogen and EGF-like domains 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of SNED1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 9:100,380,487...100,439,125
Ensembl chr 9:100,380,515...100,437,056
|
|
G |
Soat2 |
sterol O-acyltransferase 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of SOAT2 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 7:143,754,892...143,767,989
Ensembl chr 7:143,754,892...143,767,989
|
|
G |
Socs1 |
suppressor of cytokine signaling 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of SOCS1 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr10:4,956,795...4,958,472
Ensembl chr10:4,957,326...4,958,461
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of SOCS3 mRNA] |
CTD |
PMID:19910459 |
|
NCBI chr10:106,973,863...106,976,969
Ensembl chr10:106,975,178...106,976,040
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
Cannabidiol inhibits the reaction [3-nitropropionic acid results in decreased expression of SOD1 mRNA] |
CTD |
PMID:17672854 |
|
NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
EXP |
Cannabidiol inhibits the reaction [3-nitropropionic acid results in decreased expression of SOD2 mRNA] |
CTD |
PMID:17672854 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Sox4 |
SRY-box transcription factor 4 |
increases expression |
ISO |
Cannabidiol results in increased expression of SOX4 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr17:37,615,022...37,619,728
|
|
G |
Sphk1 |
sphingosine kinase 1 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of SPHK1 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr10:105,498,728...105,504,401
Ensembl chr10:105,498,728...105,504,393
|
|
G |
Spic |
Spi-C transcription factor |
increases expression |
ISO |
Cannabidiol results in increased expression of SPIC mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 7:29,225,721...29,233,452
Ensembl chr 7:29,225,727...29,233,392
|
|
G |
Sqstm1 |
sequestosome 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of SQSTM1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
affects methylation increases expression |
EXP ISO |
Cannabidiol affects the methylation of SRC gene Cannabidiol results in increased expression of SRC mRNA |
CTD |
PMID:30521419 PMID:30742662 |
|
NCBI chr 3:153,547,807...153,595,643
Ensembl chr 3:153,580,861...153,595,642
|
|
G |
Srxn1 |
sulfiredoxin 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of SRXN1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 3:147,608,850...147,614,410
Ensembl chr 3:147,609,095...147,632,801
|
|
G |
St6galnac4 |
ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 4 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of ST6GALNAC4 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 3:11,607,103...11,619,595
Ensembl chr 3:11,607,225...11,619,593
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of STAT1 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 9:54,287,540...54,327,958
Ensembl chr 9:54,287,541...54,484,533
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of and results in increased activity of STAT3 protein] |
CTD |
PMID:19910459 |
|
NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
|
|
G |
Stx11 |
syntaxin 11 |
increases expression |
ISO |
Cannabidiol results in increased expression of STX11 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:7,039,160...7,064,870
Ensembl chr 1:7,039,162...7,064,870
|
|
G |
Tac1 |
tachykinin, precursor 1 |
multiple interactions |
EXP |
Cannabidiol inhibits the reaction [3-nitropropionic acid results in decreased expression of TAC1 mRNA] |
CTD |
PMID:17672854 |
|
NCBI chr 4:33,638,853...33,646,819
Ensembl chr 4:33,638,709...33,646,819
|
|
G |
Tagap |
T-cell activation RhoGTPase activating protein |
multiple interactions |
ISO |
Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of TAGAP mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 1:47,493,990...47,503,492
Ensembl chr 1:47,493,994...47,502,952
|
|
G |
Tbx3 |
T-box transcription factor 3 |
affects methylation |
EXP |
Cannabidiol affects the methylation of TBX3 gene |
CTD |
PMID:30521419 |
|
NCBI chr12:42,479,518...42,494,588
Ensembl chr12:42,480,560...42,492,526
|
|
G |
Tcf7l1 |
transcription factor 7 like 1 |
affects methylation |
EXP |
Cannabidiol affects the methylation of TCF7L1 gene |
CTD |
PMID:30521419 |
|
NCBI chr 4:100,492,796...100,660,401
Ensembl chr 4:100,491,798...100,660,140
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
[Dronabinol co-treated with Cannabidiol] inhibits the reaction [TGFB1 protein results in increased expression of CDH2 mRNA]; [Dronabinol co-treated with Cannabidiol] inhibits the reaction [TGFB1 protein results in increased expression of VIM mRNA]; Cannabidiol inhibits the reaction [TGFB1 protein results in increased expression of CDH2 mRNA]; Cannabidiol inhibits the reaction [TGFB1 protein results in increased expression of VIM mRNA] |
CTD |
PMID:32049991 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Tgfb3 |
transforming growth factor, beta 3 |
affects methylation |
EXP |
Cannabidiol affects the methylation of TGFB3 gene |
CTD |
PMID:30521419 |
|
NCBI chr 6:109,913,757...109,936,217
Ensembl chr 6:109,913,757...109,935,533
|
|
G |
Tgfbr2 |
transforming growth factor, beta receptor 2 |
affects methylation |
EXP |
Cannabidiol affects the methylation of TGFBR2 gene |
CTD |
PMID:30521419 |
|
NCBI chr 8:124,310,288...124,399,345
Ensembl chr 8:124,312,754...124,399,494
|
|
G |
Tgif2 |
TGFB-induced factor homeobox 2 |
multiple interactions |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of TGIF2 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 3:152,906,961...152,924,380
Ensembl chr 3:152,909,189...152,924,377
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of TIMP1 mRNA; Cannabidiol results in increased expression of TIMP1 protein ICAM1 mutant form inhibits the reaction [Cannabidiol results in increased expression of TIMP1 protein] |
CTD |
PMID:22198381 |
|
NCBI chr X:1,364,771...1,369,451
Ensembl chr X:1,364,786...1,369,384
|
|
G |
Tle1 |
TLE family member 1, transcriptional corepressor |
decreases expression |
ISO |
Cannabidiol results in decreased expression of TLE1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 5:88,546,607...88,630,277
Ensembl chr 5:88,546,568...88,629,491
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP ISO |
Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of TNF mRNA; Cannabidiol analog inhibits the reaction [Peptidoglycan results in increased expression of TNF protein]; Cannabidiol analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNF protein] [Cannabidiol co-treated with TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA; Cannabidiol analog inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Cannabidiol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in decreased expression of TRPV1 mRNA]; Cannabidiol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA]; Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] |
CTD |
PMID:21492165 PMID:30742662 PMID:30796934 PMID:31054246 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnfaip2 |
TNF alpha induced protein 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of TNFAIP2 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 6:135,890,869...135,903,647
Ensembl chr 6:135,890,931...135,903,647
|
|
G |
Tnfrsf18 |
TNF receptor superfamily member 18 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of TNFRSF18 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 5:173,459,371...173,463,980
Ensembl chr 5:173,460,354...173,463,140
|
|
G |
Tnfrsf9 |
TNF receptor superfamily member 9 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of TNFRSF9 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 5:168,009,245...168,035,813
Ensembl chr 5:168,009,393...168,035,810
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of TNFSF11 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr15:60,482,527...60,512,704
Ensembl chr15:60,482,527...60,512,704
|
|
G |
Tnfsf14 |
TNF superfamily member 14 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of TNFSF14 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 9:9,761,363...9,765,461
Ensembl chr 9:9,761,536...9,765,186
|
|
G |
Tnfsf8 |
TNF superfamily member 8 |
multiple interactions |
ISO |
Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of TNFSF8 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 5:79,664,779...79,691,547
Ensembl chr 5:79,664,765...79,691,258
|
|
G |
Top2a |
DNA topoisomerase II alpha |
multiple interactions decreases activity |
ISO |
Cannabidiol metabolite inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]; Dithiothreitol inhibits the reaction [Cannabidiol metabolite inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]] Cannabidiol metabolite results in decreased activity of TOP2A protein |
CTD |
PMID:29272108 |
|
NCBI chr10:86,901,467...86,930,947
Ensembl chr10:86,901,007...86,932,154
|
|
G |
Top2b |
DNA topoisomerase II beta |
multiple interactions decreases activity |
ISO |
Cannabidiol metabolite inhibits the reaction [TOP2B protein results in increased hydrolysis of Adenosine Triphosphate] Cannabidiol metabolite results in decreased activity of TOP2B protein |
CTD |
PMID:29272108 |
|
NCBI chr15:10,262,972...10,319,741
Ensembl chr15:10,262,651...10,320,233
|
|
G |
Tp53 |
tumor protein p53 |
decreases expression |
EXP |
Cannabidiol results in decreased expression of TP53 mRNA |
CTD |
PMID:32553926 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Tp53inp1 |
tumor protein p53 inducible nuclear protein 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of TRP53INP1 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 5:24,402,895...24,419,651
Ensembl chr 5:24,410,863...24,416,888
|
|
G |
Tpm3 |
tropomyosin 3 |
affects methylation |
EXP |
Cannabidiol affects the methylation of TPM3 gene |
CTD |
PMID:30521419 |
|
NCBI chr 2:189,423,534...189,451,340
Ensembl chr 2:189,423,559...189,451,029
|
|
G |
Traf1 |
TNF receptor-associated factor 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of TRAF1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 3:14,003,340...14,022,955
Ensembl chr 3:14,003,340...14,022,672
|
|
G |
Traf3 |
Tnf receptor-associated factor 3 |
affects methylation |
EXP |
Cannabidiol affects the methylation of TRAF3 gene |
CTD |
PMID:30521419 |
|
NCBI chr 6:135,610,698...135,720,247
Ensembl chr 6:135,610,743...135,718,564
|
|
G |
Trat1 |
T cell receptor associated transmembrane adaptor 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of TRAT1 mRNA |
CTD |
PMID:27256343 |
|
NCBI chr11:54,619,169...54,661,284
Ensembl chr11:54,619,129...54,662,353
|
|
G |
Trib3 |
tribbles pseudokinase 3 |
increases expression |
ISO |
Cannabidiol results in increased expression of TRIB3 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 3:147,814,056...147,819,650
Ensembl chr 3:147,813,473...147,819,571
|
|
G |
Trpa1 |
transient receptor potential cation channel, subfamily A, member 1 |
multiple interactions |
EXP |
Cannabidiol binds to and results in increased activity of TRPA1 protein |
CTD |
PMID:18550765 |
|
NCBI chr 5:3,783,247...3,836,485
Ensembl chr 5:3,783,247...3,836,485
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions increases activity |
ISO |
[Cannabidiol results in increased activity of TRPV1 protein] which results in increased uptake of Calcium; Cannabidiol inhibits the reaction [[Capsaicin binds to TRPV1 protein] which results in increased uptake of Calcium]; Cannabidiol inhibits the reaction [[resiniferatoxin binds to TRPV1 protein] which results in increased uptake of Calcium]; Cannabidiol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in decreased expression of TRPV1 mRNA]; Cannabidiol inhibits the reaction [Capsaicin binds to TRPV1 protein]; Cannabidiol inhibits the reaction [resiniferatoxin binds to TRPV1 protein]; capsazepine inhibits the reaction [[Cannabidiol results in increased activity of TRPV1 protein] which results in increased uptake of Calcium]; capsazepine inhibits the reaction [Cannabidiol results in increased activity of TRPV1 protein]; TRPV1 protein promotes the reaction [Cannabidiol results in decreased secretion of SERPINE1 protein] |
CTD |
PMID:11606325 PMID:20668920 PMID:31054246 PMID:31096838 |
|
NCBI chr10:59,799,123...59,824,208
Ensembl chr10:59,799,123...59,824,679
|
|
G |
Trpv2 |
transient receptor potential cation channel, subfamily V, member 2 |
increases activity multiple interactions |
ISO EXP |
Cannabidiol results in increased activity of TRPV2 protein [Cannabidiol results in increased activity of TRPV2 protein] which results in increased uptake of Calcium Cannabidiol analog binds to and results in increased activity of TRPV2 protein; Cannabidiol binds to and results in increased activity of TRPV2 protein |
CTD |
PMID:18550765 PMID:31096838 |
|
NCBI chr10:48,903,540...48,925,036
Ensembl chr10:48,903,540...48,925,030
|
|
G |
Tubb2b |
tubulin, beta 2B class IIb |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of TUBB2B mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr17:31,441,640...31,444,687
Ensembl chr17:31,441,630...31,482,759
|
|
G |
Tyr |
tyrosinase |
multiple interactions increases expression |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cannabidiol results in increased activity of TYR protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cannabidiol results in increased expression of TYR mRNA]; Cannabidiol results in increased expression of and results in increased activity of TYR protein; SB 203580 inhibits the reaction [Cannabidiol results in increased activity of TYR protein]; SB 203580 inhibits the reaction [Cannabidiol results in increased expression of TYR mRNA] |
CTD |
PMID:28601556 |
|
NCBI chr 1:151,012,598...151,106,802
Ensembl chr 1:151,012,598...151,106,802
|
|
G |
Tyrp1 |
tyrosinase-related protein 1 |
multiple interactions increases expression |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cannabidiol results in increased expression of TYRP1 mRNA]; SB 203580 inhibits the reaction [Cannabidiol results in increased expression of TYRP1 mRNA] Cannabidiol results in increased expression of TYRP1 mRNA; Cannabidiol results in increased expression of TYRP1 protein |
CTD |
PMID:28601556 |
|
NCBI chr 5:98,387,291...98,406,083
Ensembl chr 5:98,387,291...98,406,083
|
|
G |
Usp2 |
ubiquitin specific peptidase 2 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of USP2 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 8:48,403,985...48,432,525
Ensembl chr 8:48,406,260...48,430,885
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of VEGFA mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of VEGFA mRNA |
CTD |
PMID:21542829 PMID:30742662 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Vegfb |
vascular endothelial growth factor B |
affects methylation |
EXP |
Cannabidiol affects the methylation of VEGFB gene |
CTD |
PMID:30521419 |
|
NCBI chr 1:222,237,000...222,242,786
Ensembl chr 1:222,239,022...222,242,644
|
|
G |
Vim |
vimentin |
multiple interactions |
ISO |
[Dronabinol co-treated with Cannabidiol] inhibits the reaction [TGFB1 protein results in increased expression of VIM mRNA]; Cannabidiol inhibits the reaction [TGFB1 protein results in increased expression of VIM mRNA] |
CTD |
PMID:32049991 |
|
NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212
|
|
G |
Vps37b |
VPS37B subunit of ESCRT-I |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of VPS37B mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr12:37,984,790...38,023,369
Ensembl chr12:37,984,790...38,023,368
|
|
G |
Vwf |
von Willebrand factor |
increases expression |
ISO |
Cannabidiol results in increased expression of VWF mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 4:158,085,059...158,219,525
Ensembl chr 4:158,088,505...158,219,523
|
|
G |
Wasf2 |
WASP family member 2 |
affects methylation |
EXP |
Cannabidiol affects the methylation of WASF2 gene |
CTD |
PMID:30521419 |
|
NCBI chr 5:151,319,382...151,385,051
Ensembl chr 5:151,343,493...151,381,238
|
|
G |
Wnt1 |
Wnt family member 1 |
multiple interactions |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of WNT1 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 7:140,464,999...140,469,046
Ensembl chr 7:140,464,999...140,469,046
|
|
G |
Wnt11 |
Wnt family member 11 |
affects methylation |
EXP |
Cannabidiol affects the methylation of WNT11 gene |
CTD |
PMID:30521419 |
|
NCBI chr 1:163,794,136...163,813,756
Ensembl chr 1:163,797,660...163,813,756
|
|
G |
Wnt7b |
Wnt family member 7B |
affects methylation |
EXP |
Cannabidiol affects the methylation of WNT7B gene |
CTD |
PMID:30521419 |
|
NCBI chr 7:126,423,418...126,465,724
Ensembl chr 7:126,420,656...126,465,723
|
|
G |
Xbp1 |
X-box binding protein 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of XBP1 mRNA |
CTD |
PMID:32033040 |
|
NCBI chr14:85,753,736...85,758,820
Ensembl chr14:85,753,760...85,758,145
|
|
G |
Xcl1 |
X-C motif chemokine ligand 1 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of XCL1 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr13:83,199,402...83,202,845
Ensembl chr13:83,199,264...83,202,864
|
|
|
G |
Bhlhe41 |
basic helix-loop-helix family, member e41 |
increases expression |
ISO |
cannabidiolic acid results in increased expression of BHLHE41 mRNA |
CTD |
PMID:25242400 |
|
NCBI chr 4:180,230,742...180,235,138
Ensembl chr 4:180,232,382...180,234,804
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
ISO |
cannabidiolic acid results in decreased expression of FOS mRNA |
CTD |
PMID:27530354 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
increases expression |
ISO |
cannabidiolic acid results in increased expression of HTR1A mRNA |
CTD |
PMID:27530354 |
|
NCBI chr 2:36,246,628...36,247,896
Ensembl chr 2:36,246,628...36,247,896
|
|
G |
Id1 |
inhibitor of DNA binding 1, HLH protein |
decreases expression |
ISO |
cannabidiolic acid results in decreased expression of ID1 mRNA |
CTD |
PMID:25242400 |
|
NCBI chr 3:148,214,623...148,216,715
Ensembl chr 3:148,215,540...148,216,718
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression multiple interactions |
ISO |
cannabidiolic acid results in decreased expression of PTGS2 mRNA cannabidiolic acid inhibits the reaction [GW 501516 results in increased expression of PTGS2 mRNA]; cannabidiolic acid promotes the reaction [GSK0660 results in decreased expression of PTGS2 mRNA] |
CTD |
PMID:25242400 PMID:27530354 PMID:32238697 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Trpa1 |
transient receptor potential cation channel, subfamily A, member 1 |
increases activity |
ISO |
cannabidiolic acid results in increased activity of TRPA1 protein |
CTD |
PMID:31096838 |
|
NCBI chr 5:3,783,247...3,836,485
Ensembl chr 5:3,783,247...3,836,485
|
|
G |
Trpm8 |
transient receptor potential cation channel, subfamily M, member 8 |
decreases expression |
ISO |
cannabidiolic acid results in decreased expression of TRPM8 mRNA |
CTD |
PMID:27530354 |
|
NCBI chr 9:95,393,370...95,484,528
Ensembl chr 9:95,398,237...95,482,890
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
increases activity multiple interactions |
ISO |
cannabidiolic acid results in increased activity of TRPV1 protein [cannabidiolic acid results in increased activity of TRPV1 protein] which results in increased uptake of Calcium |
CTD |
PMID:31096838 |
|
NCBI chr10:59,799,123...59,824,208
Ensembl chr10:59,799,123...59,824,679
|
|
G |
Trpv2 |
transient receptor potential cation channel, subfamily V, member 2 |
multiple interactions increases expression |
ISO |
[cannabidiolic acid results in increased activity of TRPV2 protein] which results in increased uptake of Calcium cannabidiolic acid results in increased expression of TRPV2 mRNA |
CTD |
PMID:27530354 PMID:31096838 |
|
NCBI chr10:48,903,540...48,925,036
Ensembl chr10:48,903,540...48,925,030
|
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
EXP |
cannabigerol inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein] |
CTD |
PMID:22971837 |
|
NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
multiple interactions |
ISO |
cannabigerol affects the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to CNR2 protein] |
CTD |
PMID:22971837 |
|
NCBI chr 5:154,242,010...154,268,126
Ensembl chr 5:154,260,062...154,268,126
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
cannabigerol inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein] |
CTD |
PMID:22971837 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
cannabigerol inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:22971837 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
cannabigerol inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] |
CTD |
PMID:22971837 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions increases activity |
ISO |
[cannabigerol results in increased activity of TRPV1 protein] which results in increased uptake of Calcium |
CTD |
PMID:31096838 |
|
NCBI chr10:59,799,123...59,824,208
Ensembl chr10:59,799,123...59,824,679
|
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions increases activity |
ISO |
[cannabigerolic acid results in increased activity of TRPV1 protein] which results in increased uptake of Calcium |
CTD |
PMID:31096838 |
|
NCBI chr10:59,799,123...59,824,208
Ensembl chr10:59,799,123...59,824,679
|
|
|
G |
Fosb |
FosB proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
delta(9)-tetrahydrocannabinolic acid results in increased expression of FOSB protein alternative form |
CTD |
PMID:18293355 |
|
NCBI chr 1:80,214,691...80,221,417
Ensembl chr 1:80,214,494...80,221,710
|
|
|
G |
Arg1 |
arginase 1 |
multiple interactions |
EXP |
HU 308 promotes the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of ARG1 mRNA] |
CTD |
PMID:29560022 |
|
NCBI chr 1:21,525,421...21,537,872
Ensembl chr 1:21,525,421...21,537,863
|
|
G |
Atg5 |
autophagy related 5 |
multiple interactions |
ISO |
ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein]] |
CTD |
PMID:27611972 |
|
NCBI chr20:49,301,783...49,393,147
Ensembl chr20:49,318,308...49,393,140
|
|
G |
Becn1 |
beclin 1 |
multiple interactions |
ISO |
[HU 308 co-treated with Dextran Sulfate] affects the expression of BECN1 protein; HU 308 inhibits the reaction [Glucose results in decreased expression of BECN1 protein]; HU 308 inhibits the reaction [Streptozocin results in decreased expression of BECN1 protein]; HU 308 promotes the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein] |
CTD |
PMID:27611972 PMID:30459625 |
|
NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
3-methyladenine affects the reaction [[HU 308 co-treated with Dextran Sulfate] affects the cleavage of CASP1 protein]; [HU 308 co-treated with Dextran Sulfate] affects the cleavage of CASP1 protein; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; dorsomorphin inhibits the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein] |
CTD |
PMID:27611972 |
|
NCBI chr 8:2,605,743...2,614,637
Ensembl chr 8:2,604,962...2,614,631
|
|
G |
Cd68 |
Cd68 molecule |
multiple interactions |
EXP |
HU 308 inhibits the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of CD68 protein] |
CTD |
PMID:29560022 |
|
NCBI chr10:56,268,726...56,270,605
Ensembl chr10:56,268,720...56,270,640
|
|
G |
Chi3l3 |
chitinase 3-like 3 |
multiple interactions |
EXP |
HU 308 promotes the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of CHI3L3 mRNA] |
CTD |
PMID:29560022 |
|
NCBI chr 2:208,899,871...208,936,858
Ensembl chr 2:208,900,103...208,936,860
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
multiple interactions |
EXP ISO |
HU 308 promotes the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of CNR2 mRNA]; HU 308 promotes the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of CNR2 protein] [HU 308 co-treated with lipopolysaccharide, E. coli O26-B6] results in increased expression of CNR2 mRNA |
CTD |
PMID:29560022 PMID:30232034 |
|
NCBI chr 5:154,242,010...154,268,126
Ensembl chr 5:154,260,062...154,268,126
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO EXP |
HU 308 promotes the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of IL10 protein] HU 308 promotes the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of IL10 mRNA] |
CTD |
PMID:29560022 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP ISO |
HU 308 inhibits the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of IL1B mRNA] 3-methyladenine affects the reaction [[HU 308 co-treated with Dextran Sulfate] affects the expression of IL1B protein]; [HU 308 co-treated with Dextran Sulfate] affects the expression of IL1B protein; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein]]; dorsomorphin inhibits the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of IL1B protein]]; HU 308 inhibits the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of IL1B protein]; HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of and results in increased secretion of IL1B protein]; HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein] |
CTD |
PMID:27611972 PMID:29560022 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP ISO |
HU 308 inhibits the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of IL6 mRNA] HU 308 inhibits the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of IL6 protein] |
CTD |
PMID:29560022 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Mrc1 |
mannose receptor, C type 1 |
multiple interactions |
EXP |
HU 308 promotes the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of MRC1 protein] |
CTD |
PMID:29560022 |
|
NCBI chr17:81,352,700...81,433,743
Ensembl chr17:81,352,700...81,433,743
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
EXP ISO |
HU 308 inhibits the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased phosphorylation of MTOR protein] HU 308 inhibits the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased phosphorylation of MTOR protein]; HU 308 inhibits the reaction [Glucose results in increased phosphorylation of MTOR protein] |
CTD |
PMID:29560022 PMID:30459625 |
|
NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
EXP ISO |
HU 308 inhibits the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:29560022 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
[HU 308 co-treated with Dextran Sulfate] affects the expression of NLRP3 protein |
CTD |
PMID:27611972 |
|
NCBI chr10:45,884,324...45,918,290
Ensembl chr10:45,893,018...45,918,254
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO EXP |
HU 308 inhibits the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of NOS2 protein] |
CTD |
PMID:29560022 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
multiple interactions |
EXP |
HU 308 promotes the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased phosphorylation of PIK3R1 protein] |
CTD |
PMID:29560022 |
|
NCBI chr 2:31,742,326...31,826,882
Ensembl chr 2:31,745,088...31,826,867
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
ISO |
HU 308 inhibits the reaction [Glucose results in increased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:30459625 |
|
NCBI chr10:73,824,200...73,865,503
Ensembl chr10:73,824,202...73,865,364
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
ISO |
[HU 308 co-treated with Dextran Sulfate] affects the expression of SQSTM1 protein; HU 308 inhibits the reaction [Glucose results in increased expression of SQSTM1 protein]; HU 308 inhibits the reaction [Streptozocin results in increased expression of SQSTM1 protein]; HU 308 promotes the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in decreased expression of SQSTM1 protein] |
CTD |
PMID:27611972 PMID:30459625 |
|
NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP ISO |
HU 308 promotes the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of TGFB1 mRNA] HU 308 promotes the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of TGFB1 protein] |
CTD |
PMID:29560022 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP ISO |
HU 308 inhibits the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of TNF mRNA] HU 308 inhibits the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of TNF protein] |
CTD |
PMID:29560022 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases response to substance multiple interactions |
ISO |
PPARA results in increased susceptibility to N-oleoylethanolamine N-oleoylethanolamine binds to and results in increased activity of PPARA protein |
CTD |
PMID:17906680 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
ISO |
N-oleoylethanolamine results in decreased expression of PTGS2 protein |
CTD |
PMID:17906680 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
|
G |
Apob |
apolipoprotein B |
affects folding |
ISO |
palmidrol affects the folding of APOB protein |
CTD |
PMID:16115474 |
|
NCBI chr 6:33,176,826...33,216,381
Ensembl chr 6:33,176,778...33,224,997
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
multiple interactions |
ISO |
[palmidrol co-treated with TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA; palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA] |
CTD |
PMID:31054246 |
|
NCBI chr 5:57,423,735...57,429,252
Ensembl chr 5:57,423,734...57,429,245
|
|
G |
Aqp4 |
aquaporin 4 |
affects expression |
ISO |
palmidrol affects the expression of AQP4 mRNA |
CTD |
PMID:31054246 |
|
NCBI chr18:6,766,009...6,782,757
Ensembl chr18:6,765,945...6,782,996
|
|
G |
Cldn3 |
claudin 3 |
multiple interactions decreases expression |
ISO |
[TNF protein co-treated with IFNG protein co-treated with palmidrol] results in decreased expression of CLDN3 mRNA palmidrol results in decreased expression of CLDN3 mRNA |
CTD |
PMID:31054246 |
|
NCBI chr12:21,831,341...21,832,813
Ensembl chr12:21,831,342...21,832,813
|
|
G |
Cldn5 |
claudin 5 |
decreases expression |
ISO |
palmidrol results in decreased expression of CLDN5 mRNA |
CTD |
PMID:31054246 |
|
NCBI chr11:86,356,292...86,357,718
Ensembl chr11:86,356,294...86,357,718
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions |
EXP |
[rimonabant binds to and results in decreased activity of CNR1 protein] which results in decreased susceptibility to palmidrol analog |
CTD |
PMID:17558434 |
|
NCBI chr 5:49,307,584...49,333,064
Ensembl chr 5:49,311,030...49,333,056
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
affects binding multiple interactions |
ISO EXP |
palmidrol binds to CNR2 protein [SR 144528 binds to and results in decreased activity of CNR2 protein] which results in decreased susceptibility to palmidrol analog |
CTD |
PMID:10617657 PMID:10688601 PMID:17558434 |
|
NCBI chr 5:154,242,010...154,268,126
Ensembl chr 5:154,260,062...154,268,126
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
multiple interactions |
EXP |
palmidrol analog inhibits the reaction [[Streptozocin co-treated with iomeprol] results in increased expression of GSTA1 protein] |
CTD |
PMID:26474837 |
|
NCBI chr 9:27,366,404...27,381,004
Ensembl chr 9:27,368,272...27,452,902
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[palmidrol co-treated with TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA; [TNF protein co-treated with IFNG protein co-treated with palmidrol] results in decreased expression of CLDN3 mRNA; palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in decreased expression of TRPV1 mRNA]; palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA] |
CTD |
PMID:31054246 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Lcn2 |
lipocalin 2 |
multiple interactions |
EXP |
palmidrol analog inhibits the reaction [[Streptozocin co-treated with iomeprol] results in increased expression of LCN2 protein] |
CTD |
PMID:26474837 |
|
NCBI chr 3:11,414,189...11,417,534
Ensembl chr 3:11,414,186...11,417,546
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions affects localization |
EXP |
[MK-886 binds to and results in decreased activity of PPARA protein] which results in decreased susceptibility to palmidrol analog; [palmidrol co-treated with glyceryl 2-arachidonate] affects the localization of PPARA protein; [palmidrol co-treated with glyceryl 2-arachidonate] affects the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of PPARA protein] palmidrol affects the localization of PPARA protein |
CTD |
PMID:17558434 PMID:31787870 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
[palmidrol co-treated with TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA; [TNF protein co-treated with IFNG protein co-treated with palmidrol] results in decreased expression of CLDN3 mRNA; palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in decreased expression of TRPV1 mRNA]; palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA] |
CTD |
PMID:31054246 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions |
ISO |
palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in decreased expression of TRPV1 mRNA] |
CTD |
PMID:31054246 |
|
NCBI chr10:59,799,123...59,824,208
Ensembl chr10:59,799,123...59,824,679
|
|
|
G |
Abca2 |
ATP binding cassette subfamily A member 2 |
decreases expression |
ISO |
Win 55212-2 results in decreased expression of ABCA2 mRNA |
CTD |
PMID:12237329 |
|
NCBI chr 3:2,648,787...2,668,770
Ensembl chr 3:2,648,885...2,668,809
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
affects activity |
ISO |
Win 55212-2 affects the activity of ABCG2 protein |
CTD |
PMID:30083819 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions |
ISO |
Win 55212-2 inhibits the reaction [IL6 protein results in decreased phosphorylation of ACACA protein] |
CTD |
PMID:27324222 |
|
NCBI chr10:71,519,392...71,719,910
Ensembl chr10:71,536,533...71,719,910
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions decreases expression |
ISO |
JTE 907 inhibits the reaction [Win 55212-2 analog results in decreased expression of ACTA2 protein]; Win 55212-2 inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] Win 55212-2 inhibits the reaction [Bleomycin results in increased expression of ACTA2 mRNA]; Win 55212-2 inhibits the reaction [Bleomycin results in increased expression of ACTA2 protein] |
CTD |
PMID:31901889 PMID:31991773 |
|
NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
|
|
G |
Adora2a |
adenosine A2a receptor |
decreases response to substance |
EXP |
ADORA2A protein results in decreased susceptibility to Win 55212-2 |
CTD |
PMID:26526685 |
|
NCBI chr20:14,265,251...14,282,873
Ensembl chr20:14,265,252...14,282,873
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation multiple interactions |
ISO EXP |
Win 55212-2 results in increased phosphorylation of AKT1 protein CNR2 protein affects the reaction [Win 55212-2 results in increased phosphorylation of and results in increased activity of AKT1 protein]; Win 55212-2 results in increased phosphorylation of and results in increased activity of AKT1 protein |
CTD |
PMID:12734338 PMID:20619260 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
decreases expression |
ISO |
Win 55212-2 results in decreased expression of APAF1 protein |
CTD |
PMID:30776504 |
|
NCBI chr 7:31,699,309...31,784,192
Ensembl chr 7:31,699,885...31,784,192
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
Win 55212-2 inhibits the reaction [APP alternative form results in increased expression of IL6 mRNA] |
CTD |
PMID:21350020 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Arg1 |
arginase 1 |
multiple interactions affects expression |
ISO |
AM6545 inhibits the reaction [Win 55212-2 affects the expression of ARG1 mRNA] |
CTD |
PMID:30184259 |
|
NCBI chr 1:21,525,421...21,537,872
Ensembl chr 1:21,525,421...21,537,863
|
|
G |
Arhgdia |
Rho GDP dissociation inhibitor alpha |
decreases expression |
ISO |
Win 55212-2 results in decreased expression of ARHGDIA mRNA |
CTD |
PMID:12237329 |
|
NCBI chr10:109,754,012...109,757,506
Ensembl chr10:109,754,004...109,757,550
|
|
G |
Arrb1 |
arrestin, beta 1 |
multiple interactions |
ISO |
GRK2 protein affects the reaction [Win 55212-2 promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]]; Win 55212-2 affects the reaction [CNR1 protein affects the localization of ARRB1 protein]; Win 55212-2 promotes the reaction [CNR2 protein affects the localization of ARRB1 protein] |
CTD |
PMID:31024316 |
|
NCBI chr 1:164,502,099...164,573,947
Ensembl chr 1:164,502,389...164,593,139
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
ISO |
[Win 55212-2 co-treated with CNR2 protein] affects the localization of ARRB2 protein; Win 55212-2 promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; Win 55212-2 promotes the reaction [CNR2 protein affects the localization of ARRB2 protein] |
CTD |
PMID:31024316 PMID:31901889 |
|
NCBI chr10:57,040,252...57,048,045
Ensembl chr10:57,040,267...57,048,134
|
|
G |
Becn1 |
beclin 1 |
decreases expression |
ISO |
Win 55212-2 results in decreased expression of BECN1 protein |
CTD |
PMID:30776504 |
|
NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297
|
|
G |
Casp3 |
caspase 3 |
decreases cleavage |
ISO |
Win 55212-2 results in decreased cleavage of CASP3 protein |
CTD |
PMID:30776504 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp7 |
caspase 7 |
decreases cleavage |
ISO |
Win 55212-2 results in decreased cleavage of CASP7 protein |
CTD |
PMID:30776504 |
|
NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
|
|
G |
Casp8 |
caspase 8 |
decreases cleavage |
ISO |
Win 55212-2 results in decreased cleavage of CASP8 protein |
CTD |
PMID:30776504 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases activity |
ISO |
AM 281 inhibits the reaction [Win 55212-2 results in increased activity of CASP9 protein] |
CTD |
PMID:28495606 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cct7 |
chaperonin containing TCP1 subunit 7 |
decreases expression |
ISO |
Win 55212-2 results in decreased expression of CCT7 mRNA |
CTD |
PMID:12237329 |
|
NCBI chr 4:117,235,023...117,252,265
Ensembl chr 4:117,235,023...117,252,265
|
|
G |
Cdk14 |
cyclin-dependent kinase 14 |
increases expression |
ISO |
Win 55212-2 results in increased expression of CDK14 mRNA |
CTD |
PMID:12237329 |
|
NCBI chr 4:25,825,567...26,419,443
Ensembl chr 4:25,825,567...26,419,127
|
|
G |
Cited2 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 |
increases expression |
ISO |
Win 55212-2 results in increased expression of CITED2 mRNA; Win 55212-2 results in increased expression of CITED2 protein |
CTD |
PMID:12237329 |
|
NCBI chr 1:12,823,363...12,825,806
Ensembl chr 1:12,823,363...12,825,786
|
|
G |
Cldn1 |
claudin 1 |
multiple interactions |
ISO |
[Win 55212-2 co-treated with Dextran Sulfate] results in decreased expression of CLDN1 protein |
CTD |
PMID:27920472 |
|
NCBI chr11:77,815,216...77,830,373
Ensembl chr11:77,815,181...77,830,416
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions affects response to substance decreases expression affects localization increases activity affects binding |
ISO EXP |
CNR1 affects the reaction [Win 55212-2 results in increased activity of MAPK1 protein]; CNR1 affects the reaction [Win 55212-2 results in increased activity of MAPK3 protein]; Pertussis Toxin inhibits the reaction [Win 55212-2 results in increased activity of CNR1]; Rimonabant inhibits the reaction [Win 55212-2 results in increased activity of CNR1]; Win 55212-2 affects the reaction [CNR1 protein affects the localization of ARRB1 protein]; Win 55212-2 binds to and results in increased activity of CNR1 protein; Win 55212-2 inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to CNR1 protein]; Win 55212-2 promotes the reaction [CNR1 protein affects the localization of ARRB2 protein] CNR1 protein mutant form affects the susceptibility to Win 55212-2 Win 55212-2 results in decreased expression of CNR1 mRNA; Win 55212-2 results in decreased expression of CNR1 protein Win 55212-2 affects the localization of CNR1 protein [Rimonabant binds to and results in decreased activity of CNR1 protein] which results in decreased susceptibility to Win 55212-2; [Win 55212-2 binds to and results in increased activity of CNR1 protein] affects the reaction [Potassium Chloride results in increased transport of Calcium]; AM 251 inhibits the reaction [Win 55212-2 results in decreased expression of CNR1 mRNA]; AM 251 inhibits the reaction [Win 55212-2 results in decreased expression of CNR1 protein]; CNR1 protein affects the reaction [Win 55212-2 inhibits the reaction [Potassium Chloride results in increased transport of Calcium]]; Rimonabant inhibits the reaction [[Win 55212-2 binds to and results in increased activity of CNR1 protein] inhibits the reaction [Potassium Chloride results in increased transport of Calcium]]; Win 55212-2 binds to and results in increased activity of CNR1 protein [Win 55212-2 binds to and results in increased activity of CNR1 protein] which results in increased expression of FOS protein; CNRIP1 protein inhibits the reaction [Win 55212-2 affects the localization of CNR1 protein]; Win 55212-2 binds to and results in increased activity of CNR1 protein Win 55212-2 binds to CNR1 protein |
CTD |
PMID:8526880 PMID:10871313 PMID:12421626 PMID:12560108 PMID:16438957 PMID:17572696 PMID:21281698 PMID:22044209 PMID:22971837 PMID:27513693 PMID:29113897 PMID:30165669 PMID:30629988 PMID:31024316 |
|
NCBI chr 5:49,307,584...49,333,064
Ensembl chr 5:49,311,030...49,333,056
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
affects response to substance multiple interactions affects binding |
ISO EXP |
CNR2 gene SNP affects the susceptibility to Win 55212-2 [Win 55212-2 co-treated with CNR2 protein] affects the localization of ARRB2 protein; GRK2 protein affects the reaction [Win 55212-2 promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]]; ridaifen-B inhibits the reaction [Win 55212-2 binds to and results in increased activity of CNR2 protein]; Win 55212-2 binds to and results in increased activity of CNR2 protein; Win 55212-2 inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to CNR2 protein]; Win 55212-2 promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]; Win 55212-2 promotes the reaction [CNR2 protein affects the localization of ARRB2 protein] Win 55212-2 binds to CNR2 protein [SR 144528 binds to and results in decreased activity of CNR2 protein] which results in decreased susceptibility to Win 55212-2; CNR2 protein affects the reaction [Win 55212-2 results in increased phosphorylation of and results in increased activity of AKT1 protein]; CNR2 protein affects the reaction [Win 55212-2 results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR2 protein affects the reaction [Win 55212-2 results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Win 55212-2 binds to and results in increased activity of CNR2 protein |
CTD |
PMID:10688601 PMID:12734338 PMID:17572696 PMID:20124950 PMID:21281698 PMID:21871882 PMID:22044209 PMID:22971837 PMID:29906493 PMID:31024316 PMID:31901889 |
|
NCBI chr 5:154,242,010...154,268,126
Ensembl chr 5:154,260,062...154,268,126
|
|
G |
Cnrip1 |
cannabinoid receptor interacting protein 1 |
multiple interactions |
ISO |
CNRIP1 protein inhibits the reaction [Win 55212-2 affects the localization of CNR1 protein] |
CTD |
PMID:27513693 |
|
NCBI chr14:100,217,547...100,247,235
Ensembl chr14:100,217,289...100,247,235
|
|
G |
Ctsd |
cathepsin D |
increases expression |
ISO |
Win 55212-2 results in increased expression of CTSD protein |
CTD |
PMID:30776504 |
|
NCBI chr 1:215,541,570...215,553,446
Ensembl chr 1:215,541,542...215,553,451
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression |
ISO |
Acetylcysteine inhibits the reaction [Win 55212-2 results in increased expression of DDIT3 mRNA]; methyl-beta-cyclodextrin inhibits the reaction [Win 55212-2 results in increased expression of DDIT3 mRNA] |
CTD |
PMID:30502353 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Efs |
embryonal Fyn-associated substrate |
decreases expression |
ISO |
Win 55212-2 results in decreased expression of EFS mRNA |
CTD |
PMID:12237329 |
|
NCBI chr15:33,579,952...33,590,217
Ensembl chr15:33,578,381...33,589,522
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions increases phosphorylation |
ISO |
RTKI cpd inhibits the reaction [Win 55212-2 results in increased phosphorylation of EGFR protein] |
CTD |
PMID:20619260 |
|
NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
|
|
G |
Eif4b |
eukaryotic translation initiation factor 4B |
decreases expression |
ISO |
Win 55212-2 results in decreased expression of EIF4B mRNA |
CTD |
PMID:12237329 |
|
NCBI chr 7:143,679,656...143,701,452
Ensembl chr 7:143,679,617...143,701,452
|
|
G |
Eno2 |
enolase 2 |
decreases expression multiple interactions |
ISO |
Win 55212-2 results in decreased expression of ENO2 protein Win 55212-2 inhibits the reaction [IL6 protein results in increased expression of ENO2 protein] |
CTD |
PMID:27324222 |
|
NCBI chr 4:157,285,192...157,294,090
Ensembl chr 4:157,285,179...157,294,047
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions |
ISO |
Win 55212-2 inhibits the reaction [IL1B protein results in increased expression of and results in increased activity of F3 protein]; Win 55212-2 inhibits the reaction [IL1B protein results in increased expression of F3 mRNA] |
CTD |
PMID:27556861 |
|
NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
|
|
G |
Faah |
fatty acid amide hydrolase |
multiple interactions affects expression |
ISO EXP |
[Acetaminophen co-treated with Win 55212-2] results in decreased expression of FAAH mRNA Win 55212-2 affects the expression of FAAH mRNA [Win 55212-2 co-treated with Rimonabant] affects the expression of FAAH mRNA |
CTD |
PMID:30165669 PMID:32833042 |
|
NCBI chr 5:134,852,899...134,872,095
Ensembl chr 5:134,852,875...134,871,775
|
|
G |
Faahl |
fatty-acid amide hydrolase-like |
multiple interactions |
ISO |
[Acetaminophen co-treated with Win 55212-2] results in decreased expression of FAAH mRNA |
CTD |
PMID:30165669 |
|
NCBI chr 5:134,330,204...134,349,400
Ensembl chr 5:134,331,929...134,348,995
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[Win 55212-2 binds to and results in increased activity of CNR1 protein] which results in increased expression of FOS protein |
CTD |
PMID:12560108 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Gck |
glucokinase |
increases expression |
ISO |
Win 55212-2 results in increased expression of GCK mRNA; Win 55212-2 results in increased expression of GCK protein |
CTD |
PMID:12237329 |
|
NCBI chr14:86,149,146...86,191,589
Ensembl chr14:86,148,928...86,190,659
|
|
G |
Gphn |
gephyrin |
multiple interactions |
EXP |
Win 55212-2 promotes the reaction [Cocaine results in increased phosphorylation of GPHN protein] |
CTD |
PMID:32312805 |
|
NCBI chr 6:101,327,874...101,859,169
Ensembl chr 6:101,532,518...101,859,164
|
|
G |
Gpr55 |
G protein-coupled receptor 55 |
affects response to substance |
ISO |
GPR55 protein affects the susceptibility to Win 55212-2 |
CTD |
PMID:31877572 |
|
NCBI chr 9:92,961,431...93,011,157
Ensembl chr 9:92,962,738...92,963,697
|
|
G |
Gria1 |
glutamate ionotropic receptor AMPA type subunit 1 |
decreases expression |
EXP |
Win 55212-2 results in decreased expression of GRIA1 protein |
CTD |
PMID:32312805 |
|
NCBI chr10:42,441,723...42,760,200
Ensembl chr10:42,614,713...42,760,200
|
|
G |
Gria2 |
glutamate ionotropic receptor AMPA type subunit 2 |
decreases expression |
EXP |
Win 55212-2 results in decreased expression of GRIA2 protein |
CTD |
PMID:32312805 |
|
NCBI chr 2:179,584,302...179,704,629
Ensembl chr 2:179,584,308...179,704,629
|
|
G |
Grin1 |
glutamate ionotropic receptor NMDA type subunit 1 |
multiple interactions |
ISO |
Win 55212-2 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 protein] |
CTD |
PMID:28092019 |
|
NCBI chr 3:2,507,745...2,534,664
Ensembl chr 3:2,506,896...2,534,663
|
|
G |
Grk2 |
G protein-coupled receptor kinase 2 |
multiple interactions |
ISO |
GRK2 protein affects the reaction [Win 55212-2 promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]] |
CTD |
PMID:31024316 |
|
NCBI chr 1:219,536,220...219,544,329
Ensembl chr 1:219,536,220...219,544,328
|
|
G |
Hdac6 |
histone deacetylase 6 |
multiple interactions |
EXP |
Win 55212-2 promotes the reaction [Cocaine results in decreased expression of HDAC6 protein] |
CTD |
PMID:32312805 |
|
NCBI chr X:15,295,372...15,316,673
Ensembl chr X:15,295,473...15,316,671
|
|
G |
Hspb3 |
heat shock protein family B (small) member 3 |
increases expression |
ISO |
Win 55212-2 results in increased expression of HSPB3 mRNA |
CTD |
PMID:12237329 |
|
NCBI chr 2:45,517,788...45,518,502
Ensembl chr 2:45,517,789...45,518,502
|
|
G |
Htatsf1 |
HIV-1 Tat specific factor 1 |
multiple interactions |
EXP |
[Win 55212-2 co-treated with Cocaine] results in decreased phosphorylation of HTATSF1 protein |
CTD |
PMID:32312805 |
|
NCBI chr X:159,514,053...159,528,281
Ensembl chr X:159,513,800...159,528,281
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
EXP ISO |
iodopravadoline inhibits the reaction [Win 55212-2 promotes the reaction [Carbon Monoxide results in increased expression of IL10 protein]]; Win 55212-2 promotes the reaction [Carbon Monoxide results in increased expression of IL10 protein] Win 55212-2 promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL10 protein] |
CTD |
PMID:31732924 PMID:32385136 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
Win 55212-2 inhibits the reaction [IL1B protein results in increased abundance of N-palmitoylsphingosine]; Win 55212-2 inhibits the reaction [IL1B protein results in increased expression of and results in increased activity of F3 protein]; Win 55212-2 inhibits the reaction [IL1B protein results in increased expression of F3 mRNA] iodopravadoline inhibits the reaction [Win 55212-2 inhibits the reaction [Carbon Monoxide results in increased expression of IL1B protein]]; Win 55212-2 inhibits the reaction [Carbon Monoxide results in increased expression of IL1B protein] |
CTD |
PMID:27556861 PMID:31732924 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il1rl1 |
interleukin 1 receptor-like 1 |
multiple interactions |
EXP |
iodopravadoline inhibits the reaction [Win 55212-2 promotes the reaction [Carbon Monoxide results in increased expression of IL1RL1 protein]]; Win 55212-2 promotes the reaction [Carbon Monoxide results in increased expression of IL1RL1 protein] |
CTD |
PMID:31732924 |
|
NCBI chr 9:47,133,483...47,184,316
Ensembl chr 9:47,134,034...47,182,170
|
|
G |
Il33 |
interleukin 33 |
multiple interactions |
EXP |
AM 251 inhibits the reaction [Win 55212-2 promotes the reaction [Carbon Monoxide results in increased expression of IL33 protein]]; Win 55212-2 promotes the reaction [Carbon Monoxide results in increased expression of IL33 protein] |
CTD |
PMID:31732924 |
|
NCBI chr 1:248,112,611...248,147,030
Ensembl chr 1:248,132,090...248,147,029
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
EXP |
[Carbon Monoxide co-treated with Win 55212-2] results in increased expression of IL4 protein; iodopravadoline inhibits the reaction [[Carbon Monoxide co-treated with Win 55212-2] results in increased expression of IL4 protein] |
CTD |
PMID:31732924 |
|
NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
Win 55212-2 inhibits the reaction [APP alternative form results in increased expression of IL6 mRNA]; Win 55212-2 inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein] Win 55212-2 inhibits the reaction [IL6 protein results in decreased phosphorylation of ACACA protein]; Win 55212-2 inhibits the reaction [IL6 protein results in decreased phosphorylation of PRKAA1 protein]; Win 55212-2 inhibits the reaction [IL6 protein results in increased expression of ENO2 protein]; Win 55212-2 inhibits the reaction [IL6 protein results in increased expression of TUBB3 protein] |
CTD |
PMID:21350020 PMID:27324222 PMID:27920472 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Kdr |
kinase insert domain receptor |
multiple interactions |
ISO |
fumonisin B1 inhibits the reaction [Win 55212-2 results in decreased phosphorylation of and results in decreased activity of KDR protein]; Win 55212-2 results in decreased phosphorylation of and results in decreased activity of KDR protein |
CTD |
PMID:15313899 |
|
NCBI chr14:34,727,677...34,787,127
Ensembl chr14:34,727,623...34,787,183
|
|
G |
Map2 |
microtubule-associated protein 2 |
decreases expression |
ISO |
Win 55212-2 results in decreased expression of MAP2 mRNA |
CTD |
PMID:12237329 |
|
NCBI chr 9:73,204,753...73,462,965
Ensembl chr 9:73,319,710...73,462,972
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases activity increases phosphorylation |
ISO EXP |
CNR1 affects the reaction [Win 55212-2 results in increased activity of MAPK1 protein] CNR2 protein affects the reaction [Win 55212-2 results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Rimonabant inhibits the reaction [Win 55212-2 results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Win 55212-2 promotes the reaction [Cocaine results in increased expression of MAPK1 protein]; Win 55212-2 results in increased phosphorylation of and results in increased activity of MAPK1 protein Win 55212-2 results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:8526880 PMID:12657697 PMID:12734338 PMID:20619260 PMID:32312805 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases activity multiple interactions increases phosphorylation |
ISO EXP |
Win 55212-2 results in increased activity of MAPK3 protein CNR2 protein affects the reaction [Win 55212-2 results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Rimonabant inhibits the reaction [Win 55212-2 results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Win 55212-2 promotes the reaction [Cocaine results in increased expression of MAPK3 protein]; Win 55212-2 results in increased phosphorylation of and results in increased activity of MAPK3 protein Win 55212-2 results in increased phosphorylation of MAPK3 protein CNR1 affects the reaction [Win 55212-2 results in increased activity of MAPK3 protein] |
CTD |
PMID:8526880 PMID:12657697 PMID:12734338 PMID:20619260 PMID:32312805 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases phosphorylation |
ISO |
Win 55212-2 results in increased phosphorylation of MAPK8 protein |
CTD |
PMID:20619260 |
|
NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
increases phosphorylation |
ISO |
Win 55212-2 results in increased phosphorylation of MAPK9 protein |
CTD |
PMID:20619260 |
|
NCBI chr10:35,333,859...35,374,364
Ensembl chr10:35,333,859...35,374,355
|
|
G |
Mapt |
microtubule-associated protein tau |
increases expression |
ISO |
Win 55212-2 results in increased expression of MAPT mRNA |
CTD |
PMID:12237329 |
|
NCBI chr10:92,289,002...92,386,517
Ensembl chr10:92,288,910...92,386,517
|
|
G |
Mat2a |
methionine adenosyltransferase 2A |
decreases expression |
ISO |
Win 55212-2 results in decreased expression of MAT2A mRNA |
CTD |
PMID:12237329 |
|
NCBI chr 4:100,297,478...100,303,047
Ensembl chr 4:100,296,075...100,303,080
|
|
G |
Mgll |
monoglyceride lipase |
affects response to substance |
ISO |
MGLL protein affects the susceptibility to Win 55212-2 |
CTD |
PMID:21911610 |
|
NCBI chr 4:120,671,436...120,773,458
Ensembl chr 4:120,671,489...120,771,088
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases activity decreases expression multiple interactions |
ISO |
Win 55212-2 results in decreased activity of MMP2 protein Win 55212-2 analog results in decreased expression of MMP2 protein JTE 907 inhibits the reaction [Win 55212-2 analog results in decreased expression of MMP2 protein] |
CTD |
PMID:30776504 PMID:31991773 |
|
NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases activity |
ISO |
Win 55212-2 results in decreased activity of MMP9 protein |
CTD |
PMID:30776504 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Morf4l1 |
mortality factor 4 like 1 |
decreases expression |
ISO |
Win 55212-2 results in decreased expression of MORF4L1 mRNA |
CTD |
PMID:12237329 |
|
NCBI chr 8:97,473,454...97,494,974
Ensembl chr 8:97,474,092...97,494,834
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
Win 55212-2 inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein] |
CTD |
PMID:27920472 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Mrc1 |
mannose receptor, C type 1 |
multiple interactions |
EXP |
[Win 55212-2 co-treated with Carbon Monoxide] results in increased expression of MRC1 protein; iodopravadoline inhibits the reaction [[Win 55212-2 co-treated with Carbon Monoxide] results in increased expression of MRC1 protein] |
CTD |
PMID:31732924 |
|
NCBI chr17:81,352,700...81,433,743
Ensembl chr17:81,352,700...81,433,743
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
increases expression |
ISO |
Win 55212-2 results in increased expression of MYC mRNA |
CTD |
PMID:12237329 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Napepld |
N-acyl phosphatidylethanolamine phospholipase D |
multiple interactions |
EXP |
[Win 55212-2 co-treated with Rimonabant] affects the expression of NAPEPLD mRNA |
CTD |
PMID:32833042 |
|
NCBI chr 4:9,965,323...10,004,650
Ensembl chr 4:9,966,891...10,002,247
|
|
G |
Ndrg4 |
NDRG family member 4 |
decreases expression |
ISO |
Win 55212-2 results in decreased expression of NDRG4 mRNA |
CTD |
PMID:12237329 |
|
NCBI chr19:9,766,439...9,802,396
Ensembl chr19:9,766,439...9,801,942
|
|
G |
Nedd4l |
NEDD4 like E3 ubiquitin protein ligase |
decreases expression |
ISO |
Win 55212-2 results in decreased expression of NEDD4L mRNA |
CTD |
PMID:12237329 |
|
NCBI chr18:60,392,376...60,719,720
Ensembl chr18:60,392,376...60,719,720
|
|
G |
Nfatc4 |
nuclear factor of activated T-cells 4 |
increases localization |
EXP |
Win 55212-2 results in increased localization of NFATC4 protein |
CTD |
PMID:16849427 |
|
NCBI chr15:34,493,163...34,502,238
Ensembl chr15:34,493,138...34,504,326
|
|
G |
Npas2 |
neuronal PAS domain protein 2 |
multiple interactions |
EXP |
Win 55212-2 promotes the reaction [Cocaine results in increased splicing of NPAS2 mRNA] |
CTD |
PMID:32312805 |
|
NCBI chr 9:45,901,262...46,081,880
Ensembl chr 9:45,901,741...46,081,880
|
|
G |
Ntn1 |
netrin 1 |
increases expression |
ISO |
Win 55212-2 results in increased expression of NTN1 mRNA |
CTD |
PMID:12237329 |
|
NCBI chr10:54,761,925...54,982,072
Ensembl chr10:54,761,871...54,967,585
|
|
G |
Ntrk2 |
neurotrophic receptor tyrosine kinase 2 |
multiple interactions |
ISO |
[Acetaminophen co-treated with Win 55212-2] results in decreased expression of NTRK2 mRNA |
CTD |
PMID:30165669 |
|
NCBI chr17:5,934,651...6,245,778
Ensembl chr17:5,933,729...6,244,676
|
|
G |
Pacsin1 |
protein kinase C and casein kinase substrate in neurons 1 |
decreases expression |
ISO |
Win 55212-2 results in decreased expression of PACSIN1 mRNA |
CTD |
PMID:12237329 |
|
NCBI chr20:7,241,248...7,286,702
Ensembl chr20:7,279,820...7,286,586
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
decreases expression |
ISO |
Win 55212-2 results in decreased expression of PARP1 protein |
CTD |
PMID:30776504 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Perp |
p53 apoptosis effector related to PMP22 |
increases expression |
ISO |
Win 55212-2 results in increased expression of PERP mRNA |
CTD |
PMID:12237329 |
|
NCBI chr 1:14,224,392...14,236,838
Ensembl chr 1:14,224,393...14,236,846
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
Win 55212-2 binds to and results in increased activity of PPARA protein |
CTD |
PMID:17906680 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Ppp2r1a |
protein phosphatase 2 scaffold subunit A alpha |
decreases expression |
ISO |
Win 55212-2 results in decreased expression of PPP2R1A mRNA |
CTD |
PMID:12237329 |
|
NCBI chr 1:60,717,386...60,736,629
Ensembl chr 1:60,717,386...60,736,609
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
ISO |
Win 55212-2 inhibits the reaction [IL6 protein results in decreased phosphorylation of PRKAA1 protein] |
CTD |
PMID:27324222 |
|
NCBI chr 2:54,857,688...54,893,404
Ensembl chr 2:54,857,688...54,893,404
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions affects expression |
EXP |
[Win 55212-2 co-treated with Rimonabant] affects the expression of PTEN mRNA Win 55212-2 affects the expression of PTEN mRNA |
CTD |
PMID:32833042 |
|
NCBI chr 1:251,421,814...251,487,634
Ensembl chr 1:251,421,596...251,487,832
|
|
G |
Ptgds |
prostaglandin D2 synthase |
decreases expression |
ISO |
Win 55212-2 results in decreased expression of PTGDS mRNA |
CTD |
PMID:12237329 |
|
NCBI chr 3:2,686,125...2,689,059
Ensembl chr 3:2,686,123...2,689,084
|
|
G |
Ptprn |
protein tyrosine phosphatase, receptor type, N |
decreases expression |
ISO |
Win 55212-2 results in decreased expression of PTPRN mRNA |
CTD |
PMID:12237329 |
|
NCBI chr 9:82,446,626...82,462,314
Ensembl chr 9:82,446,633...82,461,903
|
|
G |
Rfc1 |
replication factor C subunit 1 |
increases expression |
ISO |
Win 55212-2 results in increased expression of RFC1 mRNA |
CTD |
PMID:12237329 |
|
NCBI chr14:44,627,528...44,702,205
Ensembl chr14:44,580,216...44,702,203
|
|
G |
Ripk1 |
receptor interacting serine/threonine kinase 1 |
decreases expression |
ISO |
Win 55212-2 results in decreased expression of RIPK1 protein |
CTD |
PMID:30776504 |
|
NCBI chr17:31,537,580...31,569,904
Ensembl chr17:31,537,591...31,569,904
|
|
G |
Rtn3 |
reticulon 3 |
decreases expression |
ISO |
Win 55212-2 results in decreased expression of RTN3 mRNA |
CTD |
PMID:12237329 |
|
NCBI chr 1:222,677,359...222,734,307
Ensembl chr 1:222,677,365...222,734,241
|
|
G |
S1pr3 |
sphingosine-1-phosphate receptor 3 |
increases expression |
ISO |
Win 55212-2 results in increased expression of S1PR3 mRNA |
CTD |
PMID:12237329 |
|
NCBI chr17:13,799,383...13,812,877
Ensembl chr17:13,799,383...13,812,704
|
|
G |
Serpine2 |
serpin family E member 2 |
decreases expression |
ISO |
Win 55212-2 results in decreased expression of SERPINE2 mRNA |
CTD |
PMID:12237329 |
|
NCBI chr 9:85,560,852...85,629,410
Ensembl chr 9:85,560,863...85,626,094
|
|
G |
Slc12a5 |
solute carrier family 12 member 5 |
affects expression |
EXP |
Win 55212-2 affects the expression of SLC12A5 mRNA; Win 55212-2 affects the expression of SLC12A5 protein |
CTD |
PMID:31653479 |
|
NCBI chr 3:161,433,303...161,465,078
Ensembl chr 3:161,425,988...161,462,879
|
|
G |
Slc1a1 |
solute carrier family 1 member 1 |
increases expression |
EXP |
Win 55212-2 results in increased expression of SLC1A1 protein |
CTD |
PMID:17631920 |
|
NCBI chr 1:246,955,017...247,035,159
Ensembl chr 1:246,954,980...247,037,056
|
|
G |
Slc1a2 |
solute carrier family 1 member 2 |
increases expression |
EXP |
Win 55212-2 results in increased expression of SLC1A2 protein |
CTD |
PMID:17631920 |
|
NCBI chr 3:92,518,679...92,665,731
Ensembl chr 3:92,640,752...92,665,644
|
|
G |
Slc6a1 |
solute carrier family 6 member 1 |
multiple interactions |
ISO |
Win 55212-2 inhibits the reaction [Isoproterenol results in increased expression of SLC6A1 protein] |
CTD |
PMID:30170018 |
|
NCBI chr 4:146,258,842...146,292,176
Ensembl chr 4:146,276,862...146,292,213
|
|
G |
Slc6a3 |
solute carrier family 6 member 3 |
affects expression multiple interactions |
EXP |
Win 55212-2 affects the expression of SLC6A3 mRNA; Win 55212-2 affects the expression of SLC6A3 protein AM 251 affects the reaction [Win 55212-2 affects the expression of SLC6A3 mRNA] |
CTD |
PMID:29113897 |
|
NCBI chr 1:32,323,011...32,363,983
Ensembl chr 1:32,321,580...32,363,983
|
|
G |
Smn1 |
survival of motor neuron 1, telomeric |
decreases expression |
ISO |
Win 55212-2 results in decreased expression of SMN1 mRNA |
CTD |
PMID:12237329 |
|
NCBI chr 2:30,360,101...30,371,147
Ensembl chr 2:30,360,100...30,371,147
|
|
G |
Syp |
synaptophysin |
multiple interactions |
ISO |
[Acetaminophen co-treated with Win 55212-2] results in decreased expression of SYP mRNA |
CTD |
PMID:30165669 |
|
NCBI chr X:15,694,699...15,709,244
Ensembl chr X:15,695,566...15,707,436
|
|
G |
Tagln3 |
transgelin 3 |
decreases expression |
ISO |
Win 55212-2 results in decreased expression of TAGLN3 mRNA |
CTD |
PMID:12237329 |
|
NCBI chr11:60,072,983...60,086,552
Ensembl chr11:60,072,727...60,086,553
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
Win 55212-2 inhibits the reaction [Bleomycin results in increased expression of TGFB1 mRNA] Win 55212-2 inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] |
CTD |
PMID:31901889 PMID:31991773 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions affects expression |
EXP ISO |
AM 251 affects the reaction [Win 55212-2 affects the expression of TH mRNA] Win 55212-2 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein] Win 55212-2 affects the expression of TH mRNA; Win 55212-2 affects the expression of TH protein |
CTD |
PMID:28092019 PMID:29113897 |
|
NCBI chr 1:216,073,034...216,080,287
Ensembl chr 1:216,073,031...216,080,287
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP ISO |
iodopravadoline inhibits the reaction [Win 55212-2 inhibits the reaction [Carbon Monoxide results in increased expression of TNF protein]]; Win 55212-2 inhibits the reaction [Carbon Monoxide results in increased expression of TNF protein]; Win 55212-2 inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein] Win 55212-2 inhibits the reaction [Bleomycin results in increased expression of TNF mRNA]; Win 55212-2 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein] |
CTD |
PMID:12509806 PMID:27920472 PMID:31732924 PMID:31901889 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
Win 55212-2 results in increased expression of TP53 protein |
CTD |
PMID:30776504 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Traf5 |
TNF receptor-associated factor 5 |
increases expression |
ISO |
Win 55212-2 results in increased expression of TRAF5 mRNA |
CTD |
PMID:12237329 |
|
NCBI chr13:110,758,556...110,801,871
Ensembl chr13:110,758,761...110,784,209
|
|
G |
Trib3 |
tribbles pseudokinase 3 |
increases expression |
ISO |
Win 55212-2 results in increased expression of TRIB3 protein |
CTD |
PMID:16818650 |
|
NCBI chr 3:147,814,056...147,819,650
Ensembl chr 3:147,813,473...147,819,571
|
|
G |
Trim8 |
tripartite motif-containing 8 |
increases expression |
ISO |
Win 55212-2 results in increased expression of TRIM8 mRNA |
CTD |
PMID:12237329 |
|
NCBI chr 1:266,255,797...266,270,694
Ensembl chr 1:266,255,797...266,270,694
|
|
G |
Trpa1 |
transient receptor potential cation channel, subfamily A, member 1 |
multiple interactions increases response to substance |
EXP ISO |
TRPA1 promotes the reaction [Win 55212-2 results in increased abundance of Calcium]; Win 55212-2 binds to and results in increased activity of TRPA1 protein TRPA1 results in increased susceptibility to Win 55212-2 |
CTD |
PMID:18234885 PMID:18550765 |
|
NCBI chr 5:3,783,247...3,836,485
Ensembl chr 5:3,783,247...3,836,485
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions decreases phosphorylation |
EXP |
Win 55212-2 binds to and results in increased activity of TRPV1 protein Win 55212-2 results in decreased phosphorylation of TRPV1 protein |
CTD |
PMID:16849427 PMID:18550765 |
|
NCBI chr10:59,799,123...59,824,208
Ensembl chr10:59,799,123...59,824,679
|
|
G |
Tubb3 |
tubulin, beta 3 class III |
decreases expression multiple interactions |
ISO |
Win 55212-2 results in decreased expression of TUBB3 protein Win 55212-2 inhibits the reaction [IL6 protein results in increased expression of TUBB3 protein] |
CTD |
PMID:27324222 |
|
NCBI chr19:56,220,759...56,229,813
Ensembl chr19:56,220,755...56,229,813
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
Win 55212-2 results in decreased expression of and results in decreased secretion of VEGFA protein fumonisin B1 inhibits the reaction [Win 55212-2 results in decreased expression of and results in decreased secretion of VEGFA protein]; rimonabant inhibits the reaction [Win 55212-2 results in decreased expression of and results in decreased secretion of VEGFA protein]; SR 144528 inhibits the reaction [Win 55212-2 results in decreased expression of and results in decreased secretion of VEGFA protein]; Win 55212-2 results in decreased expression of and results in decreased secretion of VEGFA protein |
CTD |
PMID:15313899 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Vps26c |
VPS26 endosomal protein sorting factor C |
increases expression |
ISO |
Win 55212-2 results in increased expression of VPS26C mRNA |
CTD |
PMID:12237329 |
|
NCBI chr11:34,764,053...34,792,446
Ensembl chr11:34,764,721...34,791,993
|
|
G |
Wdr47 |
WD repeat domain 47 |
decreases expression |
ISO |
Win 55212-2 results in decreased expression of WDR47 mRNA |
CTD |
PMID:12237329 |
|
NCBI chr 2:211,380,894...211,441,817
Ensembl chr 2:211,381,036...211,441,815
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
decreases expression |
ISO |
Win 55212-2 results in decreased expression of XIAP protein |
CTD |
PMID:30776504 |
|
NCBI chr X:128,409,425...128,455,786
Ensembl chr X:128,409,472...128,453,000
|
|
G |
Znrf1 |
zinc and ring finger 1 |
increases expression |
ISO |
Win 55212-2 results in increased expression of ZNRF1 mRNA |
CTD |
PMID:12237329 |
|
NCBI chr19:43,750,205...43,834,962
Ensembl chr19:43,750,278...43,832,878
|
|